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ANDROGEN RECEPTOR AND PROSTATE
CANCER CELL HETEROGENEITY
Qu Deng, B.Med.Sci.
Advisory Professor: Dean Tang, M.D., Ph.D.
Androgen receptor (AR) plays an important role in prostate cancer (PCa)
development and has been the main therapeutic target in advanced PCa. AR expression
is heterogeneous in both primary PCa and castration resistant prostate cancer (CRPC).
However, the functional significance of AR heterogeneity in regulating PCa biology and
response to androgen/AR-targeted therapies remains unclear. The overarching
hypothesis for my Ph.D is that AR heterogeneity contributes to PCa development,
progression, and therapy resistance. A more specific postulate is that PCa cells
expressing AR (i.e, AR+) and PCa cells expressing little AR (i.e, AR-/lo) possess
intrinsically distinct biological and tumorigenic properties as well as sensitivities to ARtargeting therapies. Here I tested my hypothesis by generating RFP-tagged AR+ LNCaP
clones with zinc finger nucleases (ZFNs) and isogenic AR knockout (AR-KO) LNCaP
clones with CRISPR-cas9 technology. With the novel genetically matched clones, we
demonstrate that the AR+ and AR-KO clonal LNCaP cells manifest contrasting tumorregenerating capacities and responses to castration and AR antagonists. Specifically,
AR+ LNCaP cells are highly tumorigenic in androgen-dependent (AD) environment and
are exquisitely sensitive to androgen-deprivation therapy (ADT). On the contrary, AR-KO
LNCaP cells possess high tumor-initiating and tumor-propagating capabilities in
androgen-ablated environment. Further, AR-KO LNCaP cells are resistant to the current
AR antagonist enzalutamide. Thus, our study links AR heterogeneity to distinct castration
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and enzalutamide responses and suggests the urgency in developing novel therapeutics
to target AR-/lo PCa cells/clones.
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Chapter 1. Introduction
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This chapter is based on two published works: Deng, Q. and Tang, D.G.,
Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical
implications. Endocrine-Related Cancer, 2015. 22(6): p. T209-20. [1]. And Liu, X., Chen,
X., Rycaj, K., Chao, H.P., Deng, Q., Jeter, C., Liu, C., Honorio, S., Li, H., Davis, T.,
Suraneni, M., Laffin, B., Qin, J., Li, Q., Yang, T., Whitney, P., Shen, J., Huang, J., and
Tang, D.G., Systematic dissection of phenotypic, functional, and tumorigenic
heterogeneity of human prostate cancer cells. Oncotarget, 2015. 6(27): p. 23959-86. [2]
No permission is required.
1.1.

Cancer stem cells and tumor heterogeneity
Clonal evolution, driven by genetic instability in cancer cells, generates cellular

heterogeneity within tumors. These genetically heterogeneous cellular clones are in
persistent evolution during disease progression and clinical treatment, wherein
subclones with advantageous survival attributes such as drug resistance, become
dominate and survive (Figure1-1; top). This mode of progression results in extensive
branching evolution, which can subsequently lead to variable numbers of clonal cell
expansions that define multifocal cancer. The multifocal and heterogeneous nature of
prostate cancer (PCa) has hindered efforts to understand tumor cell clonality, and the
origin of PCa remains controversial. High-resolution genome technologies have led to
data supporting independent tumor origins as well as a monoclonal origin of multifocal
PCa. In support of the former, recent genome-wide DNA sequencing of multifocal PCa
revealed the existence of multiple independent clonal expansions within each patient [3].
Even morphologically normal regions of the prostate possessed as many as ten genetic
mutations, with several shared by cancer samples within the same patient, suggesting
these clones existed prior to the formation of the distinct cancer lineages. The recent use
2

of next generation sequencing has led to an expansion in our understanding of the
complex genetic basis of PCa. Genetic alterations, such as TMPRSS2-ERG fusion and
PTEN deletion within tumor clones, have been shown to activate critical signaling
pathways such as ERG and PI3K, thus driving clonal evolution in patients with “high-risk”
primary PCa [4]. In an effort to identify genomic alterations that characterize a
monoclonal origin of a lethal metastatic cell clone in a patient with CRPC (castrationresistant prostate cancer), authors of a recent study found that during 17 years of tumor
progression, only the tumor clones with PTEN, P53 and SPOP (Speckle-type POZ
protein) mutations gained additional genetic alterations and gave rise to lethal metastatic
tumors [5]. Surprisingly, the lethal clone (defined by the presence of the same PTEN,
P53, and SPOP mutations) in this patient was found to arise from a morphologically lowgrade (Gleason 3) tumor focus instead of from the predominant Gleason 4 tumor foci.
Whole-genome exome sequencing in 50 lethal, and heavily pre-treated metastatic
CRPCs also confirmed the monoclonal origin of lethal CRPC [6]. Regardless of origin,
these examples highlight the importance of genetically-driven clonal evolution in driving
PCa progression.
Additionally, there is also strong evidence that tumor cells within a genetically
identical clone possess different tumorigenic abilities and, in most cases, are organized
in a hierarchical manner [7-9] (Figure1-1; bottom). Sitting at the apex of this tumorigenic
hierarchy, in untreated tumors, is the small subset of stem-like cancer cells, or cancer
stem cells (CSCs) that possess high self-renewal and differentiation ability. In other
words, CSCs can sustain an established tumor clone through unlimited self-renewal and
maintain intraclonal heterogeneity through generating both tumorigenic and less or nontumorigenic cancer cells. Similar to normal hematopoietic stem cells (HSCs), which are
3

among the best-understood adult stem cells, the best-characterized CSCs are CSCs in
leukemia or leukemic stem cells [8]. Like HSCs, LSCs are undifferentiated lacking the
expression of lineage differentiation markers. Subsequent studies have led to the
identification of CSCs in multiple human solid tumors and a common phenotypic feature
appears to be the lack of differentiation markers and regulators [7-9].
In a strict sense, CSCs in human tumors are defined as a population of cancer
cells, when prospectively purified from patient tumors, xenografts, and even long-term
cultures, can regenerate and also indefinitely propagate human tumors in immunedeficient mice. In reality, CSC properties of a candidate population of human tumor cells
are best assessed by performing limiting dilution tumor-regeneration assays combined
with serial tumor transplantations and cell biological (e.g., clonal in 2D; clonogenic in 3D;
sphere formation; single-cell division and differentiation; etc) as well as molecular (e.g.,
RNA-Seq and ChIP-Seq) characterizations [10]. The tumor cell population that can
initiate or regenerate tumors at low cell doses is considered to be tumor-initiating or
tumor-regenerating cells while the tumor cell population that can long-term propagate
human xenograft tumors is called tumor-propagating cells [10]. Unfortunately, many of
the reported CSC populations do not fully satisfy this strict definition. For example, some
studies only utilized cell lines to perform in vitro assays without tumor experiments,
whereas others only performed tumor experiments without carrying out further serial
transplantations. Such deficiencies have created confusion and disbelief in the field of
CSCs. Nevertheless, recent lineage tracing studies in genetically driven mouse model
tumors (i.e., glioblastoma, and intestinal and skin tumors) have provided definitive
evidence for CSCs [10].
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Figure 1-1 Unified model of clonal evolution and cancer stem cells
This figure is reproduced from Kreso, A. and Dick, J.E., Evolution of the cancer stem cell
model. Cell Stem Cell, 2014. 14(3): p. 275-91. [8] with permission of Cell Stem Cell
license Number 3963820933777.
Acquisition of favorable mutations can result in clonal expansion of the founder
cell. In parallel, another cell may gain a different mutation that allows it to form a new
subclone. Over time, genetic mutations accumulate and subclones evolve in parallel.
The bottom panel shows that it may be that CSCs are not static entities but can evolve
over the lifetime of a cancer as genetic changes can influence CSC frequency. Some
subclones may contain a steep developmental hierarchy (left), where only few selfrenewing CSCs exist among a large number of non-CSCs. Other subclones (middle)
may contain an intermediate hierarchy, where the number of CSCs is relatively high but
a hierarchy still exists. Some subclones may have the genetic alterations that confer high
self-renewal potential, where most cells are tumorigenic, as frequently observed in
advanced and treatment-failed clinical tumors. In this scenario, applying the CSC
concept to such homogeneous subclones is not warranted because most cells can selfrenew and few non-CSC progeny are generated. [8]
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1.2.

Prostate cancer stem cells (PCSCs)
The CSC model helps explain the generation of tumor cell heterogeneity from the

viewpoint of stem cell maturation and differentiation. PCa is well known to be a highly
heterogeneous malignancy, with each tumor harboring many tumor clones [3, 5].
Therefore, evidence supporting the existence of PCSC populations does not come as a
surprise [11, 12] (Figure 1-2). PCSCs are defined, more or less, using a spectrum of
classical in vitro and in vivo assays used to define CSCs (see above). In vitro, PCSCs
preferentially express stem cell and CSC-associated molecules, self-renewal genes
(e.g., Bmi-1, Stat3, Nanog, Sox2, Oct4) and possess high clonal and clonogenic
capacities. In vivo, PCSCs possess higher tumor-initiating and serial tumor-propagating
activities than non-PCSCs in immunodeficient mice [11-13]. Three papers, published in
2005, simultaneously provided the earliest proof-of-principle evidence for PCSCs: 1) the
Side Population (SP) in the LAPC9 human xenografts was enriched in tumor-initiating
cells [14]; 2) ABCG2, a surface pump protein normally involved in cellular detoxification,
mediated efflux of androgen in putative PCSCs [15]; and 3) the CD44+α2β1+CD133+
PCa cells from patient prostate tumors possessed high clonogenic survivability in
methylcellulose [16].
Our lab, since 2002, has been employing and developing a variety of
experimental strategies to elucidate the cellular basis and molecular regulation of PCa
cell heterogeneity in an effort to link PCa cell heterogeneity to therapy resistance and
tumor relapse (Figure 1-2). Virtually all of our PCSC studies have been based on tumorregeneration and, in many cases, serial tumor transplantation assays. Using the SP
analysis, we were the first to provide evidence that the SP in certain PCa xenograft
models is enriched in tumor-regenerating and tumor-propagating cells and thus satisfies
6

the strict definition of CSCs [14]. Using cell surface markers, our systematic studies have
provided convincing evidence that the CD44 high-expressing (i.e., CD44+) PCa cell
population in most, though not all, PCa models we have studied, is significantly enriched
in PCSCs with enhanced tumor-regenerating, tumor-propagating, and metastatic
capacities [2, 17-19]. Using holoclone assays, we have shown that the PCa cell
holoclones, like stem cell-enriched primary keratinocyte holoclones, possess long-term
tumor-propagating CSC properties [20]. Using lentiviral-mediated lineage tracing, we
have demonstrated that the phenotypically undifferentiated PCa cell population that lacks
the expression of PSA (i.e., PSA-/lo), harbors self-renewing long-term tumor-propagating
PCSCs, which express stem cell genes and epigenetic profiles, can undergo authentic
asymmetric cell division, and are intrinsically refractory to castration treatments [2, 7].
Similar to the heterogeneity of CSC populations observed in other tumor systems
[7], the heterogeneous PCSC pool contains CSC subsets with distinct tumorregenerating and tumor-propagating capabilities [2], supporting evidence of different
PCSC populations reported by others [16, 21-24]. Akin to the undifferentiated nature of
LSCs and other CSCs [7], a common phenotypic trait reported in PCSC populations is
the lack of expression of differentiation regulators and markers such as AR (see below),
PSA [7], and MHC molecules [21].
One of the major unresolved questions related to PCSCs is whether
subpopulations of PCa cells purified from primary patient tumors or CRPCs, truly
possess hardcore CSC properties such as the ability to regenerate tumors at the singlecell level and/or support serial tumor transplantations. Although patient tumor or early
PDX (patient-derived xenograft) derived cells have been shown, in many experimental
settings, to possess certain CSC properties (especially in vitro), the answer to this
7

question has remained unknown mainly due to the current technical difficulties in
recapitulating human PCa development in immunodeficient mice [12].
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Figure 1-2 A hypothetical model of tumorigenic heterogeneity of human PCa cells
This figure is reproduced from Liu, X., Chen, X., Rycaj, K., Chao, H.P., Deng, Q., Jeter,
C., Liu, C., Honorio, S., Li, H., Davis, T., Suraneni, M., Laffin, B., Qin, J., Li, Q., Yang, T.,
Whitney, P., Shen, J., Huang, J., and Tang, D.G., Systematic dissection of phenotypic,
functional, and tumorigenic heterogeneity of human prostate cancer cells. Oncotarget,
2015. 6(27): p. 23959-86. [2] with permission of Oncotarget
Prostate tumors contain a spectrum of cancer cells at different stages of
differentiation (marked by cells of varying colors and sizes). Undifferentiated (PSA-/lo)
PCa cells are quiescent (thus low proliferative index; below) and can undergo assymetric
cell division (ACD) developing into differentiated (PSA+) cells. The PSA-/lo PCa cells
possess long-term tumor-propagating activity. Importantly, the PSA-/lo PCa cell
population is still heterogeneous containing tumorigenic subsets including the castrationresistant cells. In contrast, fully differentiated (PSA+) PCa cells, despite being highly
proliferative (thus high proliferative index, below), only undergo symmetric cell division
and possess more limited tumor-propagating capabilities.[2]

9

1.3.

Androgen receptor (AR) heterogeneity in prostate cancer
AR is a master regulator of normal prostate differentiation and development.

Human AR gene, located on chromosome Xq11-12, encodes a protein with four
functional domains: the NH2-terminal domain (NTD), the DNA binding domain (DBD),
the hinge domain and the ligand-binding domain (LBD) (Figure1-3). The AR protein is
expressed in the luminal cell layer of the prostatic glands, and AR signaling critically
regulates development, differentiation, and maintenance of the prostate as documented
in both human and animal studies. Somatic mutations of the AR gene lead to malfunction
of AR and androgen insensitivity syndrome in human, in which 46 XY individuals present
female phenotype and the prostate is absent [25]. The AR NTD knockout male mice all
have small immature testes and lack secondary reproductive organs [26].
Simanainen et. al. [27] established an AR exon 3 knockout mouse model and
observed under-developed prostate in the male mice with delayed structural and
functional differentiation of the prostate epithelium. Increased proliferation in the AR
deficient epithelium was also observed [27]. In another prostate-specific AR knockout
mouse model, Wu et. al. [28] also reported increased proliferation and less differentiation
of the epithelium. These genetic studies suggest that AR promotes prostate
differentiation and suppresses epithelium proliferation in the mature prostate; in this
manner, AR signaling maintains the homeostasis and relative dormancy of mature
prostate epithelium. Consistent with this pro-differentiation role of AR, prostate epithelialspecific AR knockout promoted TRAMP tumor development, providing genetic evidence
for the tumor-suppressive function of AR [29].
Somewhat paradoxically, however, AR expression is frequently overexpressed in
PCa and, in fact, AR is thought to be required for prostate tumorigenesis and hence,
10

targeting AR and AR signaling has long been a therapeutic strategy. Androgendeprivation therapy (ADT) aims to block androgen synthesis (e.g., Abiraterone) or AR
functions (e.g., bicalutamide, Enzalutamide). Nevertheless, AR expression has been
observed to be heterogeneous in primary, and in particular, in treatment-failed patient
tumors.
Ruizeveld

de

Winter

et.

al.

[30]

examined

AR

expression

via

immunohistochemistry (IHC) staining in 26 primary PCa, and found that 7 cases
presented considerable heterogeneity in AR expression as well as a decrease in the
proportion of AR-expressing cells in more aggressive tumors. Similar AR IHC staining by
Masai et. al. [31] revealed that AR expression correlated inversely with grade. Also,
Chodak et. al. [32] analyzed AR expression in 57 untreated PCa and observed that AR
content was significantly higher in differentiated tumors compared to that of poorly
differentiated tumors. Immunofluorescence (IF) analysis of AR and PSA proteins in 11
untreated primary patient tumors in our lab showed that both AR+ and ARsubpopulations of PCa cells could be identified in all samples, although, as expected, the
AR+PSA+ PCa cells represented the major subpopulation (Figure 1-4 and 1-5). The ARPCa cells in primary (untreated) PCa samples represented ~5 - 30% of the total (Figure
1-4D) [2]. Overall, these and many other studies suggest that, although AR- cells may
not constitute the dominant cell population in treatment naïve tumors, all primary prostate
tumors nevertheless harbor both AR+ and AR- cells and clones.
AR heterogeneity in hormone-refractory PCa has been observed since the early
1990’s. van der Kwast et. al. [33] examined AR expression in CRPC and found that in
13/17 tumors, over 80% of the tumor cells were AR+. However, 3 tumors showed a
considerable heterogeneity in AR expression and in 1 sample, nearly all tumor cells
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appeared AR-/lo. Sadi et. al. [34] observed similar AR heterogeneity in needle biopsy
specimens of 17 patients with Stage D PCa. Ruizeveld de Winter et. al. [35] examined
AR expression in locally progressive CRPC and found that less differentiated PCa cells
tended towards diminished AR expression. Computer qualification of nuclear AR levels
in PCa patient samples showed that the AR concentration per cell was significantly more
heterogeneous in poor responders [36]. AR expression varies in metastases as well.
Shah et. al. [37] investigated AR expression via IHC staining in metastatic lesions of 30
CRPC patients who underwent warm autopsy, and observed wide variations in AR
expression between tumor samples. Specifically, 31% (83 of 265) of metastatic samples
had <50% AR+ cells and 41.5% (100/265) metastases had <10% AR+ cells. Five patient
metastases had <1% AR+ cells [37]. Similarly, Davis et. al. [38] reported that both AR+
cells and AR staining intensity decreased in metastatic CRPC cells compared with
benign tissues or untreated PCa. Of note, two commonly used PCa cell lines, Du145 and
PC3, which were derived from brain and bone metastasis, respectively, and possess
high tumorigenic and metastatic capacities, lack AR expression. ARCaP cells, derived
from the ascites fluid of a disseminated CRPC, express little AR [39]. Bone metastases
MDA PCa 118a/118b also completely lack AR (and PSA) expression [40].
My colleagues and I analyzed AR and PSA protein expression in 23 CRPC
samples including 20 samples (CRPC1–20) (Figure 1-6A) in a tissue microarray (TMA)
and 3 regular CRPC (CRPC21–23) samples (Figure 1-6B). AR expression showed wide
variability in these CRPC samples. For example, CRPC5 and CRPC12 showed
increased AR expression and an increase in AR+ PCa cells compared to untreated PCa;
but many CRPC samples (e.g., CRPC9, 16, and 20–23) significantly lacked AR+ PCa
cells (Figure 1-6). Furthermore, in all AR+ CRPC samples, AR− PCa cells could be
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readily identified, e.g., in CRPC8 and CRPC2 and CRPC7. In sharp contrast to AR
expression patterns, the majority of the 23 CRPC samples lacked appreciable PSA
expression and PSA+ PCa cells (Figure 1-6). Only one sample (CRPC12) was found to
have concordant AR and PSA expression and only CRPC19 (the patient was treated
with Lupron for ~2 weeks) expressed high intratumoral PSA (Figure 1-6 B). The IHC
studies in this CRPC cohort indicate that AR heterogeneity is more prominent in CRPC
than primary PCa, but PSA−/lo PCa cells (which can be AR+ or AR−) are enriched in
CRPC patient samples [2].
Subsequently, we investigated the relative abundance of the 4 subtypes of PCa
cells (i.e., AR+/PSA+, AR+/PSA-, AR-/PSA+, AR-/PSA-) in 3 AD (androgen-dependent) and
AI (androgen-independent) PCa xenograft models (LNCaP, LAPC4 and LAPC9) [7]. In
all 3 models, the AI tumors were highly enriched in PSA−/lo PCa cells (Figure 1-7). In
LNCaP AD tumors, ~80% of the cells were AR+PSA+ and the other 3 subtypes of cells
represented the minority (Figure 1-7, A and B). In contrast, the LNCaP AI tumors showed
greatly reduced AR+PSA+ cells and dramatically increased PSA−/lo (AR+PSA−/lo and
AR−PSA−/lo) cells (Figure 1-7, A and B). Similarly, PSA−/lo PCa cells were significantly
increased in LAPC4 (Figure 1-7, C) and LAPC9 (not shown) AI tumors. Interestingly, in
LAPC4 AI tumors, most AR localized to the cytoplasm (Figure 1-7, C).
Similar AR heterogeneity has also been observed in prostatic-specific transgenic
mouse models. In ARR2Pb driven c-Myc (i.e., Hi-Myc) model [41], the residual tumors
five months post-castration expressed low and heterogeneous levels of cytoplasmic AR
compared to the intact mice. These castration-resistant Hi-Myc tumor cells were also
quiescent as confirmed by negative Ki67 staining [41]. In prostate-specific Pten-deleted
mouse prostate, although most tumor cells expressed AR after 10 weeks’ castration, the
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expression level was weaker and more diffuse compared to the hormonally intact
prostate [42].
AR heterogeneity in CRPCs has a genetic basis. Recent sequencing efforts in a
cohort comprised of 150 patients with metastatic CRPC suggested that genetic
alterations of AR (mutations, amplifications) become enriched in CRPCs (~63% patients)
compared to those in untreated tumors [43]. In addition to mutations in AR itself,
alterations of members in the AR signaling pathway were also observed in metastatic
CRPCs, including FOXA1 and NCOR1/2, among others. Similarly, by comparing 50
lethal CRPCs and 11 primary PCa, Grasso et. al. [6] identified mutations in FOXA1 and
MLL2 in CRPCs that likely change the AR signaling in treatment-failed tumors.
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Figure 1-3 Genomic organization of the AR gene and overall domain structure of
the AR protein.
This figure is reproduced from Deng, Q. and Tang, D.G., Androgen receptor and prostate
cancer stem cells: biological mechanisms and clinical implications. Endocrine-Related
Cancer, 2015. 22(6): p. T209-20. [1] with the permission of Endocrine-Related Cancer.
The AR gene, located on the long arm of X chromosome and spanning 186.5 kb,
It contains eight exons interrupted by introns of various lengths (indicated below). The
AR transcript is 10.6 kb with exon 1 coding for the N-terminus domain (NTD), exons 2
and 3 the DNA binding domain (DBD) and exons 4-8 the hinge and Ligand binding
domain (LBD). The full-length AR protein contains 919 amino acids, consisting of a very
flexible NTD and constant DBD, hinge domain and LBD. The constitutively active AF1
domain is located in the NTD and the LBD consists of the AF2 domain. [1]
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Figure 1-4 Heterogeneous and discordant PSA and AR protein expression in PCa
This figure is adapted from Liu, X., Chen, X., Rycaj, K., Chao, H.P., Deng, Q., Jeter, C.,
Liu, C., Honorio, S., Li, H., Davis, T., Suraneni, M., Laffin, B., Qin, J., Li, Q., Yang, T.,
Whitney, P., Shen, J., Huang, J., and Tang, D.G., Systematic dissection of phenotypic,
functional, and tumorigenic heterogeneity of human prostate cancer cells. Oncotarget,
2015. 6(27): p. 23959-86. [2] with permission of Oncotarget
Representative immunofluorescence images (×400) illustrating heterogeneous and
discordant PSA and AR protein expression in HPCa 14 (A) and HPCa 27 (B, C) and
quantification of 4 subpopulations of PCa cells in the 9 HPCa samples (D).
In A, AR+PSA+ PCa cells are marked by red nuclei and green cytosplasm, AR+PSA−/lo
cells by red alone (panel c, white circled areas), AR− PSA+ cells by green alone (panel c,
asterisks), and AR−PSA−/lo cells by being negative (or low) for both red and green
staining (panel d, white circled area).
B-C. In HPCa 27, AR+PSA− cells are quite abundant in this sample (Bc, red alone cells;
Cc, white circled area). Rare AR−PSA+ cells can be seen by green staining alone (Cd,
white asterisk). AR−PSA− cells are negative or low for both red and green staining (Ad
and Bd, cells positive for DAPI only). [2]
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Figure 1-5 Heterogeneous and discordant PSA and AR protein expression in PCa
This figure is adapted from Liu, X., Chen, X., Rycaj, K., Chao, H.P., Deng, Q., Jeter, C.,
Liu, C., Honorio, S., Li, H., Davis, T., Suraneni, M., Laffin, B., Qin, J., Li, Q., Yang, T.,
Whitney, P., Shen, J., Huang, J., and Tang, D.G., Systematic dissection of phenotypic,
functional, and tumorigenic heterogeneity of human prostate cancer cells. Oncotarget,
2015. 6(27): p. 23959-86. [2] with permission of Oncotarget.
A. Representative immunofluorescence images (×400) illustrating 4 subpopulations of
PCa cells in HPCa 12. Although most cells are AR+PSA+ PCa cells marked by red nuclei
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and green cytoplasm, AR−PSA+ cells can be seen by green staining alone (panel c, white
circled areas), AR+PSA− cells by red staining alone (panel d, one white circled area), and
AR−PSA− cells by being negative or low for both red and green staining (panel d, dashed
white circled areas).
B. Representative immunofluorescence images (×400) illustrating 4 subpopulations of
PCa cells in HPCa 18. AR+PSA− cells are identified by red staining alone (panel c, white
circled area), AR−PSA+ cells by green staining alone (panel d, white asterisk), and
AR−PSA− cells by being negative or low for both colors (panel d, white circled area and
white arrowheads).
C-D. Representative immunofluorescence images (×400) illustrating 4 subpopulations of
PCa cells in HPCa19. AR+PSA− cells are identified by red staining alone (Cc, white
circled area and white arrow), AR−PSA+ cells are by green staining alone (Cd and Dc-d,
white asterisks), and AR−PSA− cells are by being negative (or low staining) for both
colors (Cd, white circled area).
E. Representative immunofluorescence images (×400) of AR and PSA staining in
HPCa33. This Gleason 7 tumor manifests numerous small glands in which PSA+
secretions can be observed in the lumen. There are many AR+PSA− cells (Cc, cells with
red nuclei alone) and AR−PSA− cells (Cd, cells low or negative for both red and green
signals).
F. Representative immunofluorescence images (×400) illustrating 4 subpopulations of
PCa cells in HPCa38. AR+PSA+ cells are marked by red nuclei and green cytoplasm
(panel c), AR+PSA− cells by red staining alone (panel c, white arrowheads), AR−PSA+
cells by green staining alone (panel c, white dashed circled cells), and AR−PSA− cells by
being negative or low for both red and green staining (panel d, white circled area and
many single DAPI-positive cells) [2]
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Figure 1-6 AR and PSA protein expression in CRPC
This figure is adapted from Liu, X., Chen, X., Rycaj, K., Chao, H.P., Deng, Q., Jeter, C.,
Liu, C., Honorio, S., Li, H., Davis, T., Suraneni, M., Laffin, B., Qin, J., Li, Q., Yang, T.,
Whitney, P., Shen, J., Huang, J., and Tang, D.G., Systematic dissection of phenotypic,
functional, and tumorigenic heterogeneity of human prostate cancer cells. Oncotarget,
2015. 6(27): p. 23959-86. [2] with permission of Oncotarget.
A. AR and PSA protein expression in 20 CRPC patient samples on a TMA. Shown on
right are HE (a) and AR (b) and PSA (c) IHC images of the TMA and below the TMA grid
(d). The 20 CRPC samples are in the middle (demarcated by two vertical lines whereas
several benign/normal prostate and PCa samples are shown on the top and bottom,
respectively. All samples were cut in duplicate. NP, normal prostate (i.e., no cancer); BN,
benign prostate from patients with PCa; PCa, hormone-naïve prostate cancer. CRPC1–
13, PCa patients treated with castration (mostly bicalutamide) and eventually failed after
months to years; CRPC14–17, patients failed both radiation and hormonal therapies;
CRPC18, the patient failed radiation and cryotherapy; CRPC19, the patient with
advanced PCa treated with Lupron for 2 weeks; CRPC20, the patient received 4 months
of Lupron treatment plus 2 months of Casodex.
B-C. IHC analysis of AR and PSA in TMA samples. Shown are 11 CRPC samples
illustrating prominent loss of PSA, heterogeneous expression of AR, and discordant AR
and PSA expression (insets: 400×). CRPC21 – CRPC23 were 3 separate patient CRPC
samples not included in the TMA. [2]
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Figure 1-7 Heterogeneous and discordant AR and PSA protein expression in PCa
cell models in both AD and AI conditons.
This figure is adapted from Liu, X., Chen, X., Rycaj, K., Chao, H.P., Deng, Q., Jeter, C.,
Liu, C., Honorio, S., Li, H., Davis, T., Suraneni, M., Laffin, B., Qin, J., Li, Q., Yang, T.,
Whitney, P., Shen, J., Huang, J., and Tang, D.G., Systematic dissection of phenotypic,
functional, and tumorigenic heterogeneity of human prostate cancer cells. Oncotarget,
2015. 6(27): p. 23959-86. [2] with permission of Oncotarget.
A. Double immunofluorescence staining of AR and PSA in AD vs. AI LNCaP xenograft
tumors. Arrows indicate AR−PSA+ (c) or AR−PSA−/lo (d) cells. Note significantly increased
PSA−/lo LNCaP cells in the AI tumor (f). Shown are representative immunofluorescence
images (original magnification; ×400).
B. Quantification of the 4 subtypes of PCa cells in AD and AI LNCaP xenograft tumors. A
total of 809 and 907 cells were counted from several AD and AI tumors, respectively. *P
< 0.001 in AI compared in AD tumors.
C. Double immunofluorescence staining of AR and PSA in AD vs. AI LAPC4 xenograft
tumors. In panel c, the white circle indicates several AR+PSA−/lo cells and arrows indicate
AR−PSA+ cells. In panel d, arrows point to AR−PSA−/lo cells. Note significantly increased
PSA−/lo LAPC4 cells in the AI tumor (f). Shown are representative immunofluorescence
images (original magnification; ×400). [2]
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1.4.

PCSCs in primary and untreated PCa: AR negativity and signaling

mechanisms
The preceding discussions highlight the presence of AR- PCa cells in untreated
PCa [2]. This is an important point as AR- PCa cells are expected to be unresponsive to
AR-targeting therapies. This is consistent with reports that androgen-independent PCa
cells pre-exist in primary tumors, which may be selected for during ADT [2, 44, 45].
Interestingly, AR expression is often low or undetectable in many reported PCSC
populations in untreated PCa models or primary tumors (Figure 1-8). For example,
CD44+α2β1+CD133+ cells purified from seven human tumor samples [16], ABCG2+
putative PCSCs [15], and CD44+ cells in several PCa xenografts [18] were all shown to
be AR-. In fact, AR-CD44+ PCSCs had the ability to differentiate, at the clonal level, into
AR+CD44- cells [18]. Gu et. al. [46] also showed that HPET cells (human prostate
epithelial cells immortalized by overexpressing hTERT) expressed stem cell molecules
such as CD44 and Nanog, could regenerate three prostate epithelial cell types, and were
AR negative. Miki et. al. [23] demonstrated mutually exclusive expression patterns of
CD133 and AR via IHC staining in 16 clinical specimens. Rajasekhar et. al. [24] reported
both AR and PSA negativity in the TRA-1-60+CD151+and CD166+ PCSC population,
which possessed high tumorigenic ability and could generate differentiated AR+ and
PSA+ tumors in vivo. Docetaxel-resistant PCSCs that lacked the expression of MHC
molecules were also negative for AR and PSA [21]. Likewise, the PSA-/lo PCSC
population was shown to be enriched in AR- PCa cells [2, 7]. These and many other
studies [1] suggest that PCSCs in primary and untreated tumors are generally AR-; in
other words, AR- (and PSA-) cells are highly enriched in primary and/or untreated PCSC
populations (Figure 1-8). Alternatively, loss of AR expression has been shown to
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promote PCSC generation through STAT3 signaling [47]. It remains to be seen whether
the AR+ and/or AR- PCa cells in untreated/primary PCa possess distinct self-renewal,
tumor-propagating properties and drug sensitivities as these two populations of PCa
cells have not been prospectively separated, purified, and compared.
PCSCs in untreated PCas remain AR- presumably because these cells are simply
less differentiated. Alternatively, molecules such as ABCG2 are preferentially expressed
in PCSCs [15], which mediate efflux of androgens leading to the degradation of ligandless AR in PCSCs. We have shown, via serial tumor-transplantation assays and analysis
of asymmetric cell divisions using clonal and time-lapse analyses, that several PCSC
populations (e.g., SP, CD44+, ABCG2+, and PSA-/lo) have self-renewal ability [2, 7, 14,
18]. A fraction of PSA-/lo PCa cells can undergo authentic asymmetric cell division
regenerating a PSA-/lo daughter cell as well as a differentiated PSA+ cell, which
subsequently undergoes rapid proliferation [2, 7]. Self-renewal is a shared property for
both normal stem cells and CSCs, and, not surprisingly, many molecules and pathways
that regulate self-renewal in normal stem cells have been reported to operate in PCSCs
(Figure 1-8). For example, we have shown that NANOG is preferentially expressed in
several PCSC populations and is important for CSC properties, as its knockdown
severely impairs tumor regeneration [48]. In contrast, inducible expression of NANOG
alone is sufficient to reprogram bulk cancer cells into stem-like cancer cells with
enhanced tumor-regenerating and tumor-propagating activities [49]. Our results suggest
that certain pluripotency molecules may also be functionally important for PCSC selfrenewal and other properties. In support, several other studies have similarly implicated
OCT4 and SOX2 in conferring PCSC activities [50, 51]. Interestingly, reciprocal
relationships between AR and NANOG/OCT4/SOX2 have been noted in these studies.
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Hedgehog (HH) and WNT signaling often act together and play important roles in
regulating self-renewal. The importance of WNT/β-catenin signaling is illustrated by the
observations that treatment of LNCaP and C4-2 cells with WNT-3a increased their
sphere formation rate and size, with increased nuclear β-catenin accumulation [52].
Although the AR antagonist, bicalutamide, reduced the sphere size, the sphere formation
rate did not change, thus suggesting a role of WNT signaling in PCSC self-renewal
independent from AR [52]. Bmi-1 acts down-stream of HH, and has been shown to be
necessary for HH induced self-renewal in several populations of normal stem cells as
well as CSCs [53-55]. Lukacs et. al. [56] investigated the effects of Bmi-1 loss in the
presence of over-activated Wnt signaling on murine prostate stem cells (PSCs) and
demonstrated that Bmi-1 expression was required for Wnt pathway to modulate selfrenewal in the PSCs. In addition, several other signaling molecules and pathways may
also be involved in regulating PCSCs. For example, PTEN/PI3K/AKT pathway has been
reported to be essential for PCSC proliferation independent of AR status [22].
E-twenty-six (Ets)-related gene (ERG), which is essential for adult HSC
maintenance and self-renewal during stress-induced hematopoiesis [57-59], is
deregulated in most PCa through the most common genetic event, the TMPRESS2-ERG
fusion [60-62]. TMPRSS2-ERG expression is associated with a relative increase in
clonogenic PCa cells [63]. Interestingly, although the expression of TMPRESS2-ERG
fusion gene is expected to occur in AR+ PCa cells due to the TMPRESS2 regulation by
AR, recent evidence suggests that the TMPRESS2-ERG fusion protein may also be
expressed in the AR- PCSCs. Polson and colleagues [64] demonstrated that in
CD133+α2β1+ primary tumor cells with stem cell properties, TMPRSS2-ERG and AR
expression was not necessarily concordant. While most of the marker-positive cells were
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AR negative, they expressed ERG at both RNA and protein levels, which may help
maintain PCSC properties such as self-renewal in the marker positive cells [64].
Taken together, the above discussions indicate that many well-known signaling
molecules and pathways can regulate and confer CSC properties in AR- PCSCs [11, 12].
These molecules and pathways represent obvious therapeutic targets, and therapeutics
targeting these PCSC-specific signaling nodes could, in principle, be utilized in
conjunction with the ADT regimens.
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Figure 1-8 PCSCs in untreated/primary PCa.
This figure is reproduced from Deng, Q. and Tang, D.G., Androgen receptor and prostate
cancer stem cells: biological mechanisms and clinical implications. Endocrine-Related
Cancer, 2015. 22(6): p. T209-20. [1] with the permission of Endocrine-Related Cancer.
Primary PCa contains AR+ PCa cells as the majority with the AR- PCa cells being
the minority (below). Depicted on top (left) are several representative PCSC populations
reported in primary PCa and untreated prostate tumor models, which are mostly AR- and
PSA- but have the capacity to differentiate into more mature, AR+/PSA+ PCa cells
(right). The PSA-/lo PCSC population has unlimited self-renewal potential (indicated by a
large green arrow) whereas differentiated AR+/PSA+ PCa progenitors cells have more
limited self-renewal activity (indicated by a small green arrow) [2, 7]. The PCSCs can be
positively regulated through HH (Hedgehog), WNT and PTEN signaling pathways, as
well as by transcription factors such as NANOG/SOX2/OCT4. On the other hand, several
miRNAs including miR-34a, let-7, and miR-128 have been reported to negatively
regulate PCSCs. [1]
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1.5.

PCSCs in CRPC might be AR+ or ARIt is well appreciated that AR heterogeneity is more pronounced in CRPCs than in

primary tumors (see above, [2]) and activation of alternative AR signaling in PCa cells
may promote PCa cell proliferation under androgen-deprived environments [65]. What is
the cell-of-origin of CRPCs? AR+ or AR- PCa cells? As early as 1981, Isaacs and Coffey,
working on the Dunning R3327H rat prostatic adenocarcinoma model, proposed that
castration selected for androgen-insensitive cells that pre-existed in the untreated tumors
[45]. Craft et. al. [66], working on the LAPC9 xenograft model, also provided evidence of
outgrowth of the androgen-independent clones in the later stages of CRPC development.
Fiñones et. al. [44] demonstrated androgen-independent PCa cells in untreated earlystage prostate adenocarcinomas.These androgen-independent and androgen-insensitive
PCa cells may not necessarily be AR-, because PCa cells that overexpress AR and
splice variants that lack the LBD may also be insensitive or refractory to androgen
ablation. Our recent work provided direct evidence for AR- PCa cells in primary patient
tumors [2]. As many PCSCs have been shown to be AR- and to be resistant to castration
and other therapeutics [2, 7, 11, 12], it is reasonable to postulate that the AR- PCa cells
that pre-exist in untreated tumors could be favored as ‘initiators’ or the cells-of-origin of
CRPCs (Figure 1-9). These AR- PCa cells could be expanded upon ADT-induced
elimination of AR+ cells as well as a result of the de-differentiation of AR+ PCa cells
(Figure 1-9), much like therapy- or microenvironment-induced de-differentiation of nonCSCs in other tumor systems [7, 8]. As a result, the AR- PCa cells in CRPCs may
function as the CSCs for the AR- CRPC clones (Figure 1-9). The best example is the
PSA-/lo PCSC population, which has been evinced to possess significant tumorregenerating and tumor-propagating activities in fully castrated male mice [7]. Germann
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et. al. [67] showed that PCa cells expressing stem cell markers such as ALDH1A1 and
NANOG became enriched in the BM18 castration model, and castration-resistant stemlike PCa cells had a luminal progenitor phenotype but were negative for AR. Jiao et. al.
[68] identified a CD166+ cell population in both human and mouse CRPCs, which was
enriched in basal stem/progenitor cells that were CK5+/p63+/CK8+/AR-/TROP2hi and
displayed enhanced sphere formation and tissue regeneration abilities. Also, studies on
NANOG ([48, 49] and SOX2 [51] have shown that PCa cells expressing these molecules
are castration resistant and express relatively low levels of AR. These observations raise
the possibility that the AR- PCSCs may gain growth advantages in androgen-deficient
environments, leading to distinct AR- clones in CRPC (Figure 1-9).
Despite these observations, most CRPCs clearly also have AR+ cells and clones
(Figure 1-6 [2]). Although these AR+ cells in CRPCs can potentially be derived from the
differentiation of AR- PCa cells (Figure 1-9), it is very likely that at least some AR+ PCa
cells can survive androgen deprivation and function as cells-of-origin as well as CSCs for
CRPCs (Figure 1-9). This is plausible as AR+ PCa cells in most untreated primary tumors
constitute the bulk cell population (Figure 1-9). It is conceivable that due to their
abundance, some of these AR+ PCa cells, under the selective pressure from androgen
deprivation, may selectively gain genetic alterations such as AR gene amplification and
TMPRSS2-ERG fusion, resulting in expansion of AR+ clones (Figure 1-9, right). In the
resultant AR+ PCa cell clones, AR may still be functioning to regulate both conventional
as well as new AR target genes [65]. Regulation of conventional AR targets can be
achieved through intratumoral androgen synthesis. Alternatively, AR signaling in the AR+
CRPC clones may be executed through ligand-independent AR splice variants and/or
AR crosstalks with activated receptors such as EGFR. In fact, there is evidence that
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certain AR+ cell populations are refractory to castration and can function as the cell-oforigin for PCa in mouse models. Wang et. al. [69] showed that castration-resistant
Nkx3.1-expressing cells (CARNs) that expressed luminal markers including AR,
represented a rare population of androgen-resistant cells in the murine prostate that
could function as the cells-of-origin for PCa caused by Pten deletion.
Interestingly, expressing wild-type AR at physiological levels in AR- PC3 cells
induced growth inhibition [70] whereas knocking down AR in AR-expressing metastatic
PCa cells like LNCaP and its derivative C4-2 resulted in growth inhibition, apoptotic cell
death and compromised tumor development [71, 72]. The contrasting roles of AR in ARvs. AR+ PCa cell lines imply differential involvement of AR in AR+ and AR- PCSCs in
CRPCs. Regardless, the phenotype of PCSCs in CRPCs may be context-dependent and
both AR+ and AR- clones, which possess their own intra-clonal CSCs, likely co-exist in
hormone-refractory tumors (Figure 1-9). Clarifying the precise functions of AR+ vs. ARPCSCs in CRPC awaits the development of critical experimental tools that can allow the
prospective separation of AR+ and AR- CRPC cells.
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Figure 1-9 Hypothetical PCSCs in CRPC
This figure is reproduced from Deng, Q. and Tang, D.G., Androgen receptor and prostate
cancer stem cells: biological mechanisms and clinical implications. Endocrine-Related
Cancer, 2015. 22(6): p. T209-20. [1] with the permission of Endocrine-Related Cancer.
ADT selectively targets AR+ PCa cells and has been shown to enrich AR- PCa
cells, which may result from preferential elimination by ADT of AR+ cells as well as dedifferentiation of AR+ PCa cells to AR- cells (top). Clinical CRPCs contain distinct AR+
and AR- clones, both of which might contain their own CSCs. In AR+ clones, PCSCs
could have AR amplification or ligand-independent AR signaling pathways to support the
self-renewal in androgen-deprived environment. Several potential CSC subpopulations in
AR- and AR+ PCa cell clones are indicated. [1]
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1.6.

AR and PCSCs in PCa metastasis
Metastasis is common in CRPC patients. The acquisition of invasive properties

through epithelial-mesenchymal transition (EMT), a normal development process, is
crucial for the evolution of a metastatic population [73, 74]. There is accumulating
evidence supporting the role of ADT in inducing an EMT in PCa cells [75-80],
subsequently endowing PCa cells with CSC traits. Both Tanaka et. al. [79] and
Jennbacken et. al. [76] showed that N-cadherin was upregulated in castration-resistant
LNCaP, LAPC4, and LAPC9 xenograft models. Sun et. al. [77] interrogated EMT marker
expression in mouse and human CRPC samples and observed overall higher levels of
mesenchymal markers in CRPC compared to non-castrated samples. They proposed a
negative feedback loop model between ZEB1 and AR to explain the ADT-induced EMT.
To some extent, AR signaling may be involved in the EMT switching in PCa cells. A
study on AR and ZEB2 suggests that AR may function differently between AR+ and ARcell lines [75]. Specifically, ZEB2 expression positively correlated with AR expression in
LNCaP cells, but the opposite was observed in PC3 and DU145 cells. In addition, AR
splice variants, AR3 and ARv567es, were shown to promote EMT in PCa cells [78, 80].
Not only do CSCs play an important role in tumor initiation and treatment
resistance, they may also be involved in distant metastases. Tanaka et. al. [79] have
shown that castration-resistant, N-cadherin positive PCa cells are enriched in stem cell
markers including CD44 and NANOG. Vice versa, Lin-CD44+CD133+Sca-1+CD117+
mouse PSCs express higher levels of mesenchymal markers N-cadherin and vimentin
compared to non-stem cells [77]. On the other hand, EMT may also suppress the
stemness in PCa cells [81]. This is not surprising as the mesenchymal-epithelial
transition (MET) is equally important and required for metastatic colonization. Research
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on the role of MET in PCa metastasis is very limited.
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1.7.

Clinical implications and perspectives
Studies supporting the potential prognostic role of AR in PCa are controversial,

and most evidence suggests that AR is not prognostic in PCa [82-86]. Minner et. al. [85]
examined the AR expression in more than 2800 treatment-naïve PCa patient samples
and observed no significant correlation between AR expression level and the risk of
biochemical recurrence. Studies by Fleischmann et. al. [82] in 382 lymph node
metastases reported that AR is not prognostic in nodal positive PCa, although higher AR
does correlate with a larger size of metastases. Despite significant improvements in the
ADT efficacy in blocking AR signaling, currently there are no clear correlations between
androgen signaling ablation and patient prognosis. A study by Ford et. al. [83] in 24
CRPC patients showed that 33% of patients have AR amplification, and patients with AR
gene amplification had recurrence five months earlier than those without amplification;
however, no statistically significant survival disadvantage was observed in the AR
amplified patients. More recently, Lu-Yao et. al. [84] performed a median 110-month
follow-up study in a cohort consisting of 66,717 PCa patients who underwent primary
ADT or conservative management and found that primary ADT was not associated with
improved long-term overall or disease-specific patient survival. Furthermore, AR
heterogeneity in PCa implies that targeting AR signaling as a monotherapy would be an
inefficient approach in preventing disease recurrence.
PCSCs may represent the driving force for tumor progression and metastases. A
number of studies have shown that the expression of stem-cell markers has prognostic
significance in PCa, as well as other cancer types [87, 88]. Studies on PSA-/lo PCSCs
suggest that intratumoral PSA expression is inversely correlated with tumor Gleason
score and patient survival [7]. Multiple studies have shown that AR- tumor cells are
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enriched in PCSC populations, implicating a pivotal role for PCSCs in ADT resistance.
Hence, targeting PCSCs specifically in an adjuvant setting might be helpful in preventing
CRPC. Preclinical studies targeting PCSCs have provided promising results. For
instance, we have demonstrated that microRNA-34a (miR-34a) potently inhibits PCa
progression and metastasis via directly targeting CD44 [19]. We have also reported the
suppression of PCSC self-renewal and tumor progression via several other microRNAs
including let7b and miR-128 [19, 89, 90]. At the same time, direct inhibition of WNT,
PTEN/PI3K/AKT and other cell-signaling pathways has demonstrated tumor suppressive
effects via reduction of the PCSC population [11, 91].
Understanding and elucidating the roles of and the interrelationship between AR
heterogeneity and PCSCs could offer fresh insight in designing novel therapeutics to
target lethal CRPC and metastasis. Recent evidence suggests that in untreated tumors,
PCSCs seem to be largely AR- whereas in CRPCs, PCSCs may be either AR+ or AR-. In
other words, both AR+ and AR- PCa cell clones co-exist in most CRPCs (Figure 1-9). In
principle, PCSCs, whether AR+ or AR-, are endowed with the fundamental trait of
‘stemness’, which is regulated by unique cohorts of genes, the epigenetic landscape and
environmental factors [8]. The development of novel therapeutics that target PCSC
‘stemness’ is imperative, and has the potential, when used in conjunction with ADT, to
help prevent tumor recurrence.
Two outstanding questions remain to be addressed: 1) are there intrinsic
biological and tumorigenic differences between AR+ and AR-/lo PCa cells? 2) How do the
two subpopulations of PCa cells respond to the AR targeted therapies? The overarching
hypothesis for my thesis research is that AR heterogeneity contributes to PCa
development, progression, and therapy resistance. To address the above questions
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and to test my overarching hypothesis, I propose the following two specific aims of my
research are: 1) develop novel genetic tools to separate AR+ and AR- PCa cells; and 2)
to functionally and molecularly study the isogenic AR+ and AR-KO LNCaP cells
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Chapter 2. Build AR reporter systems by using
PSA and AR promoters
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2.1.

Introduction
The impact of AR heterogeneity in PCa on cancer biology and therapy response

remains to be elucidated mainly due to the lack of tools in separating the AR+ and ARsubpopulations of PCa cells. In this chapter, we discuss the development of one method
of separating the two populations via construction of an AR reporter systems containing
PSA or AR promoters.
LNCaP cells were initially established from a PCa lymph node metastasis, and are
the most commonly used PCa cell line with ~7,000 citations in Pubmed. Regular LNCaP
cultures contain cells expressing high levels of AR (i.e., AR+) and PSA (i.e., PSA+) as
well as cells expressing little/no AR (i.e., AR-/lo) and PSA (PSA-/lo) [92]. By utilizing a PSA
promoter (PSAP) driven enhanced green fluorescence protein (eGFP) in a lentiviraltracing vector (Figure 2-1, A), we previously separated two phenotypically different but
lineage-related (i.e., PSA+ and PSA-/lo) subpopulations of PCa cells [7]. Comprehensive
cell biological, molecular, and tumor studies revealed that the phenotypically
undifferentiated PSA-/lo PCa cell population harbors self-renewing long-term tumorpropagating cells that are intrinsically refractory to castration [7].
The PSAP used in the study [7] was originally derived from a PCa patient with
high serum PSA and is highly specific and sensitive for PSA-positive PCa cells [93]. It
contains two parts of the full PSA promoter, -4703 to -3904bp and -538bp to -1bp (Figure
2-1, B), which includes 13 of the 22 putative AR response elements (AREs) in the full
PSA promoter (Figure 2-1, C). The abundance of AREs makes this an optimal promoter
to report canonical AR activity. For this reason, we fist attempted to use this PSAP-eGFP
lentivector to identify AR+ and AR-/lo cells in LNCaP cell system.
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At the same time, we constructed four AR promoter (ARP) fragments based on
previous functional analysis of the AR promoter [94]. All four AR promoter fragments
were active in various PCa cell lines [94]. Similar to our PSA-/lo studies, we used the
ARPs to drive a Red Fluorescence Protein (RFP) and aimed to report endogenous AR
expression in PCa cells. In combination with the PSAP-eGFP system, our goal was to
further dissect four phenotypically different subsets of PCa cells: AR+/PSA+, AR-/PSA+,
AR-/PSA- and AR+/PSA-.
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Figure 2-1 PSAP-GFP lentivector
A. The PSAP-eGFP lentivector, in which eGFP is driven by PSAP (PSA promoter). LTR,
long-terminal repeat; GA. gag gene; RRE, Rev responsive element.
B. Gene structure of PSA and the full promoter. The red boxes indicate parts contained
in the PSAP-eGFP vector.
C. The 22 putative AREs (Androgen-Responsive Elements) predicted by Transcription
Binding Sites Prediction (TBSP) program on PSA promoter. The 2 red boxes indicate
AREs located in the PSAP of the PSAP-eGFP vector.
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2.2.

Materials and methods

2.2.1. Cell culture and materials
LNCaP and 293FT packaging cells were obtained from ATCC (Manassas, VA)
and Invitrogen (Carlsbad, CA), respectively. LNCaP cells were cultured in RPMI 1640
(Thermo Scientific, MA) supplemented with 10% fetal bovine serum (FBS) (Thermo
Scientific, MA) and 100U/ml Penicillin-Streptomycin (PS) (Thermo Scientific, MA). 293FT
cells were cultured in DMEM (Thermo Scientific, MA) supplemented with 10% FBS and
100U/ml Penicillin-Streptomycin.
Vectors used include: pGL4.11 [luc2P] Vector (cat# E6661, Promega, Madison,
WI); pDsRed-Express-DR (Clontech Laboratories, IncMountain View, CA); and pLVXDD-tdTomato reporter vector and pLVX-DD-tdTomato Control vector (cat# 631753,
Clontech Laboratories, Inc., CA).
Antibodies used include: mouse mAb to AR (cat# sc-7305, clone 441; Santa Cruz
Biotechnology, Santa Cruz, CA); rabbit mAb to GAPDH (cat# sc-25778, clone FL-335;
Santa Cruz Biotech); rabbit pAb to PSA (cat# A0562; Dako, Carpinteria, CA); and
AlexaFlour-conjugated secondary antibodies (Invitrogen).
Restriction enzymes used include: XhoI (R0146S, NEB, Ipswich, MA); AgeI
(R0552S, NEB, Ipswich, MA); ApaI (R0114S, NEB, Ipswich, MA) BamHI (R0136S, NEB,
Ipswich, MA); and HindIII (R0104S, NEB, Ipswich, MA)
The human DNA was amplified using the following primers: 3.5 kb ARP FWD:
GGCTTTCCAGAGCAAAGAGC REV: CAGGCTGTGATGATGCGGTA. 1.7kb ARP FWD:
GAGCTCTGGACAAAATTGAGCG REV: CAGGCTGTGATGATGCGGTA. 588bp ARP
FWD: AGCCCTGGCGCCTAAACCTT REV: GGAGGACAAAGGCAGCCGTCAG. 161bp
ARP: FWD: GGAGGCCGGCCCGGTGG REV: TTTCCCTCTGTCGCCTCCT CTG. qRT39

PCR

primers:

hAR

FWD:

TTAGGGCTGGGAAGGGTCTA

REV:

ATGGGCTTGGGGAGAACCAT. hAR2 FWD: GGAGATGAAGCTTCTGGGTGT REV:
GTTGTTGTCGTGTCCAGCAC.
GCCGACCCAGCAAGATCA.

PSA

GAPDH

FWD:
FWD:

TCTGCGGCGGTGTTCTG

REV:

AATCCCATCACCATCTTCCA

REV:

TGGACTCCACGACGTACTCA
2.2.2. Lentiviral infection of LNCaP cells
PSAP-eGFP Lentivirus was produced in 293FT packaging cells and titers were
determined by GFP percentage in HT1080 cells. LNCaP cells were infected, generally,
at a multiplicity of infection (MOI) of 30 and harvested at least 72 hrs post-infection.
pLVX-ARP-DD-tdTomato lentivirus was packaged with the Lenti X™ packaging kit
(cat# 631275, Clontech Laboratories, Inc., CA) in 293FT cells and titers were determined with
Lenti-X™ GoStix™ (cat# 631243, Clontech Laboratories, Inc., CA). LNCaP cells were

infected at an MOI of 1-2. Infected cells were selected by puromycin (cat# P8833 SigmaAldrich, Inc., St. Louis, MO) at 1 µg/ml.
2.2.3. FACS and purification of the PSA+ and PSA- LNCaP Cells
At 48-72 hrs post PSAP-GFP infection, LNCaP cells were dissociated into a
single-cell suspension using trypsin/EDTA and approximately 5-10 x 106 cells were used
for FACS analysis. The top 10% GFP-bright (i.e., PSA+) cells were purified out for
functional assays as the ‘positive’ population. Generally, the bottom 2-6% cells (i.e.,
PSA-/lo) were selected as the ‘negative’ population. Post-sort analysis (i.e., qRT-PCR)
was routinely performed to assess the purity of each population.
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2.2.4. Immunofluorescence (IF) microscopy
For PSA and AR double IF staining, cells were plated on poly-lysine-coated glass
coverslips and incubated in a mix of mouse monoclonal anti-AR (clone 411, SC-7305,
Santa Cruz Technology; 1:200) and rabbit polyclonal anti-PSA (A0526, Carpinteria, CA;
1:5) in PBS containing 0.1% Triton and 5% goat serum for 2 hrs at room temperature
(RT). After thorough washing, coverslips were incubated for 60 min with secondary
antibodies (Invitrogen) Alexa Fluor 594-conjugated goat anti-mouse IgG (1:1000) and
Alexa Fluor 488-conjugated goat anti-rabbit IgG (1:1000) in PBS plus 0.1% Triton and
5% serum, followed by thorough washing. Finally, cells were stained with DAPI (H-1200;
Vector Laboratories, Burlingame, CA) for 10 min at RT, and coverslips were mounted
with 6 µL ProLong® Gold anti-fade reagent (Invitrogen). Images were acquired within 30
min on an Olympus microscope.
2.2.5. PCR, RT-PCR and qRT-PCR
For PCR, genomic DNA was extracted from 2 million clonally cultured LNCaP
cells using the Qiagen Genomic DNA mini kit (cat# 13323, Germantown, MD) and the
concentration was measured using a Nanodrop 2000 (Thermo Scientific, Waltham, MA).
For each PCR, 500ng of genomic DNA was used. For qRT-PCR, RNA was extracted
from 2 million clonal cultured cells using the Qiagen RNeasy Mini Kit (cat# 74104,
Germantown, MD), followed by cDNA synthesis using the SuperScript® III One-Step RTPCR System (cat# 12574018 Thermo Scientific, Waltham, MA). qPCR were performed
on an ABI Prism 7900HT (Applied Biosystems, Foster City, CA) with SYBR® Green PCR
Master Mix (cat# 4344463 Life tech, Carlsbad, CA).
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2.2.6. ARP-RFP reporter constructs and luciferase assays
Four sets of primers were utilized to amplify four distinct sizes of ARP fragments.
The PCR products were cloned into pCR™2.1 Vector (cat# K20001 Thermo Scientific,
Waltham, MA) for sequencing and subcloning. To construct the ARP-RFP reporter, we
cloned the ARP fragments into pDsRed-Express-DR between XhoI and AgeI sites. To
construct the pLVX-ARP-DD-tdTomato vector, we subcloned the ARP fragments into the
pLVX-DD-tdTomato reporter vector through ApaI and BamHI digestion. For luciferase
assays, we cloned the four ARP fragments into pGL4.11 [luc2P] vector (cat# E6661,
Promega, Madison, WI) via the enzyme digestion sites: XhoI and HindIII, in order to
make the reporters. LNCaP cells were seeded in 24-well plates (3 X 104 cells/well) and
co-transfected with 1 µg reporter vectors together with 10 ng Renilla luciferase internal
normalization plasmid (phRL-CMV). The ratio of firefly to Renilla luciferase activity was
determined with a dual luciferase assay (cat# E1910, Promega, Madison, WI) 48 hrs
later.
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2.3.

Results

2.3.1. Identify AR-/lo LNCaP clones using the PSAP-eGFP lentivector
Infection of LNCaP cells with the PSAP-GFP lentivector at an MOI of 30 led to an
almost 100% infected population of cells, indicating that GFP positivity faithfully reports
the endogenous PSA expression [7]. All PSA+ (i.e., GFP+) LNCaP cells expressed high
nuclear AR, whereas only ~30% PSA−/lo (i.e., GFP−/lo) LNCaP cells had strong nuclear
AR (Figure 2-2) [2]. The same is true in LAPC9 and LAPC4 cells. These observations
suggest that the PSA−/lo PCa cell population is heterogeneous with respect to AR
expression, but are enriched with AR-/lo cells LNCaP population. By exploiting this PSAPGFP model, we expect to select for AR- clones based on PSA expression.
By FACS sorting and limiting dilution, we selected and cultured multiple GFP−/lo
and GFP+ single cell clones. Consistent with previous work [7], we observed that GFP+
LNCaP cells universally developed into homogeneous GFP+ clones (Type I) (Figure 2-3,
A). In contrast GFP-/lo LNCaP cells developed into Type II (mixed GFP+/GFP-/lo clones) or
Type III (100% GFP-/lo clones) (Figure 2-3, B). In six weeks, we established 24 GFP-/lo
LNCaP single cell clones and several GFP+ LNCaP clones as the AR+ control group.
AR and PSA expression of these clones was assessed via IF staining (Figure 24). PSA staining was much lower in GFP-/lo clones compared to the control clone, IA1,
and bulk LNCaP cells. However, AR staining remained heterogeneous within each GFP/lo

and GFP+ clone. Moreover, all clones contained approximately 60% ARhi cells, as did

the bulk LNCaP cells. We further characterized AR and PSA mRNA expression between
clones via qRT-PCR (Figure 2-5). PSA mRNA expression varied in that 11 out of 23
(47%) clones exhibited lower PSA compared to the control clone, whereas clone IIB12,
IIB17, and IIB27 expressed significantly higher PSA. Overall, AR mRNA expression
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corresponded with PSA mRNA expression (R2 = 0.61). Lower levels of AR mRNA were
observed in 16 out of the 24 clones (66%) compared to the control IA1 clone, indicating
that GFP-/lo LNCaP clones were indeed enriched in ARlo cells. Nevertherless, use of this
PSAP-GFP lentivector was unsuccessful in establishing homogeneous AR-/lo LNCaP
clones.
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Figure 2-2 AR−/lo LNCaP cell population is enriched in the PSA-/lo cell population
This figure was adapted from Liu, X. et. al. 2015 [2]. No permission required.
GFP+ (i.e., PSA+) LNCaP cells expressed high levels of nuclear AR whereas GFP−/lo
(PSA−/lo) LNCaP cells were negative or weakly positive for nuclear AR. Shown are three
representative fields (×400) of purified GFP+ (left) and GFP− (right) LNCaP cells stained
for AR and DAPI, representing three independent sorts.
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Figure 2-3 Single cell cloning of the GFP+ and GFP-/lo LNCaP cells
Shown are representative GFP+ (A) and GFP-/lo (B) clonal cell images (scale bar, 500
µm)
A. Shown is one GFP+ cell that developed into a homogenous GFP+ culture (Type I
clones) in four weeks.
B. Shown are two representative GFP- clones: type II clones were a mixture of GFP+ and
GFP- cells, and type III clones were homogenous GFP- cells. [7]
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Figure 2-4 AR and PSA expression in the clones
Shown are images of the AR and PSA double IF staining.
A. AR and PSA double IF staining in bulk LNCaP cells.
B. IA1 was the PSA-GFP+ clone, in which both AR and PSA staining was strong.
C. IB1, IB3, IB4, IIB4, IIB13 and IIB16 were GFP-/lo clones, in which presented weaker
PSA staining compared to the IA1 clone and bulk LNCaP cells, but AR expression
varied between and within clones.
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Figure 2-5 AR and PSA mRNA expression levels in the clones
Shown are relative mRNA levels of AR (A) and PSA (B) of the GFP-/lo LNCaP cell clones
compared to the IA1 GFP+PSA+ clone.

48

2.3.2. Establish ARP-RFP reporters to separate AR+ and AR-/lo PCa cells
Simultaneously, in order to report the endogenous AR expression in PCa cells, we
attempted to build a different lentivector reporter in which an AR promoter (ARP) drives
red fluorescence protein (RFP). We identified four potential ARP fragments based on
research from Takane et.al. and McPhaul et.al. [94]. The Full AR promoter was defined
as the 3.5 kb fragment, from -2423 bp to +1024 bp. Takane and McPhaul identified three
regions within the full AR promoter as active ARPs in T47D, DU145 and other PCa cell
lines: the 1.7 kb fragment, from -748 bp to +1024 bp; the 588 bp fragment, from -276 bp
to +304 bp, and the 155bp, from -76bp to +87bp (Figure 2-6, A). We cloned the ARP
fragments from LNCaP genomic DNA, inserted the fragments into PGL4.11 luciferase
reporter vector (Figure 2-6, B), and confirmed that the four ARPs were active in LNCaP
cells with luciferase reporter assays (Figure 2-6, C). To test the specificity of the ARPs
for AR expression, we treated cells with 10 nM dihydrotestosterone (DHT) for 72 hrs [95].
As predicted, two of the four ARPs displayed a reduction in ARP luciferase activity, with
specifically the 3.5 kb (P = 0.0357) and 588 bp (P =0.0134) fragments showing
significant reductions. Despite confirming the activity and specificity of all four ARPs in
LNCaP cells, we opted to use only three ARPs for further experiments, due to the short
length of the 155 bp APR.
To make the ARP-DsRed reporter system, we inserted the 588 bp, 1.7 kb and 3.5
kb ARPs into the pDS-Red express-DR plasmid (Figure 2-7, A). Unfortunately, we could
only detect ~ 1% DsRed positive cells (Figure 2-7, B). To improve the lentiviral infection
delivery efficiency, we inserted the ARPs into the pLVX-DD-tdTomato lentivector in order
to make lentivirus with 293FT cells (Figure 2-8, A). By infecting LNCaP cells at an MOI of
5, we successfully achieved an 80% insertion rate, confirmed via puromycin selection
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(Figure 2-8, B). Despite this, the RFP positive cells were still too scarce for us to do
further characterization (Figure 2-8, B).
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Figure 2-6 AR promoter fragments and luciferase report assays
A. Shown is the gene structure of AR and the relative positions of the four ARP
fragments.
B. The vector map of the pGL4.11 luciferase reporter plasmid. Enzyme sites XhoI and
HindIII were used to insert the ARP fragments.
C. ARP luciferase report assay in LNCaP cells with or without 10 nM dihydrotestosterone
(DHT) treatment. * P < 0.05
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Figure 2-7 ARP-DsRed reporter studies in LNCaP cells.
A. The pDsRed-Express-DR vector map. XhoI and AgeI were used to insert the APRs.
B. Representative images of LNCaP cells 72 hrs after transfection with ARP-DsRed
reporters. The cmv-GFP vector transfection was used to show transfection efficiency.
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Figure 2-8 ARPs in pLVX-DD-tdTomato lentiviral reporter system.
A. The pLVX-DD-tdTomato construct. ApaI and BamH1 were used to insert the ARPs.
B. Representative images of LNCaP cells 72 hrs after the lentivirus infection. Cells were
infected (MOI 5) and puromycin (1 µg/ml) was used to select cells with the lentiviral
insertion. The pLVX-CMV promoter-DD-tdTomato was used as a positive infection
control. Cells without lentiviral infection served as a control (Left lower panels).
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2.4.

Discussion
In this part of study, our goal was to employ the AR or PSA promoter-reporter

system in order to conduct functional and molecular studies on highly purified
homogeneous AR+ verses AR-/lo PCa cells. We selected LNCaP cells as our primary
experimental model based on their well-documented variable expression of AR (i.e., 60%
of LNCaP cells express high levels of AR, 20% low AR and 20% AR-negative [2].
A previous study demonstrated that AR- cells were enriched in the PSA-/lo cell
population [2]. Therefore, we first utilized the PSAP-eGFP tools to select for the AR-/lo
cells. Despite low PSA expression in GFP-/lo LNCaP clones, they displayed
heterogeneous AR expression (Figure 2-4). This suggests that PSA expression is not
fully concordant with that of AR expression in PCa cells; there are AR+/PSA- and AR/PSA- PCa cells, as we previously observed in primary prostate tumor samples (Figure 14) [2]. Hence, we were unable to establish pure AR+ or AR- clones with the PSAP-eGFP
system.
We then proceeded to the AR promoter system. Compared to the PSAP, we
predicted that the ARP will theoretically be more specific for AR expression. The 4 ARP
fragments included the 3.5 kb full AR promoter and three shorter fragments. They were
active and specific in LNCaP cells based on the luciferase assays (Figure 2-6, C).
However, when ARPs were used to drive RFP in LNCaP cells, the labeling efficiency
was so limited that very few cells were RFP+. Considering that the majority of LNCaP
cells are AR+, the low RFP expression in the transfected or infected cultures suggested
low efficiency of the ARP activity. These results may be due to the fact that AR
expression may not depend solely on the 3.5 kb or the shorter promoter region, but also
on the presence of additional enhancers or post-transcriptional factors, which regulate
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AR expression in LNCaP cells. We concluded that the two non-genomic strategies we
adopted here do not seem to be sufficient to select for AR+ verses AR-/lo subpopulations.
Consequently, our next efforts focused on the generation of novel genetic models
featuring zinc finger nucleases (ZFNs) mediated integration and CRISPR-Cas9 system
mediated AR knockout.
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Chapter 3. Build AR-tagging clones with Zinc
Finger Nucleases (ZFNs)
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3.1.

Introduction
Conventional gene editing technology relies on homologous recombination (HR)

in embryonic stem (ES) cells to edit specific gene loci and generate animal models [96].
Unfortunately, targeting of specific genes and regulatory elements by virtue of HR
generally results in an extremely low number of desired recombination events, thus
presenting a huge challenge for routine use in of gene targeting. Studies have
demonstrated that DSBs (double-stand breaks) are potent inducers of recombination in
mammalian cells, and a DSB at the target locus can stimulate gene targeting by 1,000
fold [97]. Due to the limited availability of sequence-specific endonuclease in mammalian
cells, DSB-induced HR did not contribute significantly to gene targeting until recently.
Fast developing programmable nucleases, including ZFNs, transcription activator-like
effector nucleases (TALENs), and the Streptococcus pyogenes-derived CRISPR–Cas9
(clustered regularly interspaced short palindromic repeats-CRISPR-associated 9)
comprise a group of powerful gene-editing tools in human cells [98, 99]. The above three
types of nucleases operate via the same mechanisms of action: cleavage of
chromosomal DNA in a site-specific fashion triggering endogenous DNA repair systems
resulting in targeted genome modification. DSBs in the chromosome are then repaired
by nonhomologous end joining (NHEJ), which is an error-prone process that can lead to
disruption of the targeted gene. On the other hand, DSBs can be repaired by homologydirected repair (HDR), a form of HR that faithfully copies the genetic information from a
given sequence, allowing for the integration of an expression cassette into certain
genomic harbor or for the insertion of a functional copy of a disease-causing mutated
gene downstream of its own promoter [100] (Figure 3-1, C).
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The specificity of these programmable nucleases is determined by different
factors. In ZFNs, zinc-finger binding domains are engineered to recognize a DNA
sequence of interest and each zinc-finger recognizes three to four nucleotide bases
(Figure 3-1, A and B). The zinc-fingers are then fused to the nuclease domain of FokI
endonuclease to yield a highly specific ZFN. Because FokI must form a dimer to induce
a DSB, two ZFNs were needed to successfully introduce a DSB (Figure 3-1, A). In
contrast, the CRISPR–Cas9 RNA-guided DNA endonuclease is localized to a specific
DNA sequence via a single guide RNA (sgRNA) sequence. The guide RNA base pairs
with a specific targeting sequence that is adjacent to a protospacer adjacent motif (PAM)
sequence in the form of NGG or NAG. The flexibility and modularity of these geneediting tools has led to the development of numerous genome-engineering applications,
greatly facilitating cancer research [101].
To study AR heterogeneity and select for homogeneous AR positive PCa cells,
we constructed a novel AR-tagging model with ZFNs. To do this, we inserted a tag gene,
tagRFP, in frame into the C terminus of the endogenous AR locus to report AR
expression in LNCaP cells, and established multiple stable RFP+/AR+ LNCaP clones.
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Figure 3-1 Stucture and design of ZFNs, and the outcome of genome editing using
programmable nucleases
This figure is adapted from Urnov, F.D., Rebar, E.J., Holmes, M.C., Zhang, H.S., and
Gregory, P.D., Genome editing with engineered zinc finger nucleases. Nature reviews.
Genetics, 2010. 11(9): p. 636-46, [102] with the permission License number:
4033781145018
A. Sketch of a ZFN dimer bound to its target. Each ZFN contains the cleavage domain of
FokI linked to an array of three to six zinc fingers (four are shown here) that have been
designed to specifically recognize sequences (blue and red boxes) that flank the
cleavage site. A small number of bases (typically five or six) separate the ZFN targets.
B. Modular assembly of a three-finger protein from individual fingers. To generate a zinc
finger protein (ZFP) with specificity for the sequence GGGGGTGAC, three fingers are
identified that each bind a component triplet.
C. A diagram depicting various outcomes that can potentially result from the introduction
of a site-specific DNA break. A ZFN pair is shown bound to a genomic target site (the
two different DNA binding domains are shown in red and blue). The DSB generated by
ZFN cleavage induces DNA repair processes that may be influenced by the addition of
an investigator-designed donor DNA. As shown on the left, if the break is resolved via
non-homologous end joining (NHEJ) (which will occur in the absence of donor DNA), this
can lead to the following outcomes (from top to bottom): gene disruption — the two ends
can be ligated back together, frequently with loss or gain of genetic information at the
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site of the break, resulting in small insertions or deletions; tag ligation — if a doublestranded oligonucleotide is provided with overhangs complementary to those left by the
ZFNs (an adaptor), it will be ligated into the chromosome, thus producing, for example, a
tagged allele; large deletion — two simultaneous DSBs made on the same chromosome
can lead to a deletion of the entire intervening stretch. As shown in the right panels, if the
break is resolved via homology-directed repair (HDR) (which will occur in the presence of
donor DNA), this can result in (from top to bottom): gene correction — if the donor
specifies solely a single-base-pair change (for example, a restriction fragment length
polymorphism encoding a novel allele), this will result in 'gene correction' that subtly edits
the endogenous allele; targeted gene addition — if a donor is provided that carries a
transgene or multiple linked transgenes at the position corresponding to the site of the
break, the sequence will be transferred to the chromosome via the synthesis-dependent
strand annealing pathway. [102]
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3.2.

Materials and methods

3.2.1. Zinc finger nuclease design
Three customized ZFN pairs were designed to target the C terminus of AR right
before the stop codon TGA: ZFN1 (GCCCATCTATTTCCACACCCnGTGAAGCA
TTGGAA),

ZFN3

(CAAGCCCATCTATTnnnACACCCAGTGAAGCATTGGAA)

and

ZFN14 (ACCTGCTAATTAATCAAGTCACnnATGGTGAGCGTGGACTTTCCG) (Sigma,
St. Louis, MO). The vector map is shown in Figure 3-2, A.
3.2.2. Construction of donor plasmid
Donor vector contains the sequences of furin binding peptide, spacer, P2A
peptide and tagRFP cDNA. This backbone was flanked with homologous arms, which
are the sequences immediately upstream and downstream AR stop codon (Figure 3-2,
B). The original donor plasmid has two 800 bp HR arms, which were synthesized by
GeneScript (Piscataway, NJ). We synthesized two more donor plasmids with different
HR arm lengths, 300 bp and 156 bp and both 2 kb at 5’ and 3’ ends. In order to report
the activity of the donor transgene, we inserted the transgene into a pEGFP-C1
(Clontech) vector via XhoI and BamHI sites.
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Figure 3-2 ZFNs and the donor structure map
A. The ZFN vector map. CMV promoter drives the ZFN expression. Total construct size
is 4129 bp.
B. The donor plasmid map. 2395 bp of transgenes were inserted into pUC57 backbone
between XbaI and BamHI sites.
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3.2.3. Cell culture and transfections
K562, LNCaP, and PC3 cells were obtained from ATCC (Manassas, VA), and
were maintained in RPMI 1640 supplemented with 10% FBS. The first round of ZFN and
donor plasmid transfection was performed with Lipofectamine 2000. Four groups of
150,000 cells were plated in a 6-well plate one day before transfection. A mixture of 10
µL Lipofactamine 2000 carefully added to 90 µl Opi-MEM, was incubated at room
temperature (RT) for 5 min. Four separate tubes, containing 5 µg of pmaxGFP-only, 5 µg
of donor-only, 5 µg of ZFNs-only or 10 µg of ZFNs+donor, were prepared and mixed with
Opi-MEM to a total volume of 100 µl. The DNA mixtures were then carefully added, in a
drop-wise manner, to the Lipofectamine 2000 mix and incubated at RT for 20 min. After
changing the cell medium to 800 µL OpiMEM, the four DNA and lipofectamine 2000
mixtures (200 µl total) were added into separate wells, and after 8 hours, 100 µl FBS
was added to each well. A second round of ZFN and donor plasmid transfection was
done with Electroporation (Bio-rad, CA). In this experiment, 4-5x106 cells were
harvested, pelleted, washed once with 1xPBS, and suspended in Gene Pulser®
Electroporation Buffer (Bio-rad, CA) at a density of 5x106 cells/400µL. Each 400 µL
single cell suspension was then combined with the four groups of DNAs including 5 µg of
pmaxGFP, 5 µg of donor-only, 5 µg of ZFNs-only, 10 µg of ZFNs+donor, transferred to a
0.4 cm Gene Pulser® cuvette (Bio-Rad, CA) and electroporated at 200v/~mA. A third
round of ZFN and donor plasmid transfection was performed with Nucleofector™ (Lonza,

NY). In this experiment, 4-5x106 cells were harvested, washed with 10 ml HBSS twice,
and resuspended in 100 µl solution R. We then combined 100 µl containing 5x106 single
cell suspensions with four groups of DNAs including 5 µg of pmaxGFP, 5 µg of donoronly, 5 µg of ZFNs-only, or 10 µg of ZFNs+donor. The cell/DNA mixtures were then
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transferred into a nucleofector cuvette. Program T-016 was specifically used for K562
cells, T-013 for PC3 cells, and program T-009 for LNCaP and other cell lines.
3.2.4. Cel-1 assays
Genomic DNA from ZFNs-only and pmaxGFP-only cells was extracted via the
QiAamp DNA Mini Kit at 48 and 72 hrs post transfection. For PCR, 200 ng of genomic
DNA for each sample was used to amplify the genomic region around the ZFN target
sites using 5’-GGGGAGAAGTCACGCTATGA and 3’-CAAGACTTGCTCGTTCCTCC
primers. PCR products were purified with the QIAquick PCR purification kit per the
manufacturer’s instructions. PCR product from each sample (400 ng total), was eluted in
20 µl 1xGoTaq buffer, and subjected to a re-annealing process to enable heteroduplex
formation (95°C for 10 min, 95°C to 85°C ramping at -2°C/s, 85°C to 25°C at -0.1°C/s,
and 25°C hold for 1 min). After re-annealing, products were treated with 1 µL
SURVEYOR nuclease and 2 µL SURVEYOR enhancer at 42°C for one hr. Products
were then analyzed on a Novex 10% TBE gel (Life Technologies) at 240 v for 20 min.
Gels were stained with ethidium bromide (Life Technologies) for 5 min at RT and imaged
with Image Quant LAS 4000 (GE) (Figure 3-3, A).
3.2.5. Targeted integration analysis
Genomic DNA was isolated from ZFNs+donor and donor-only cells using the
QiAamp DNA Mini Kit 48 and 72 hrs post transfection. For PCR, 200 ng of genomic DNA
from each sample was used to amplify the region flanking both the 5’ and 3’ homologous
arms (Figure 3-3, B), using FWD 5’-GTGCAGCCTGTAAGCAAAC-3’ REV 5’CTTAATCAGCTCTTCGCCCTTA-3’ or FWD 5’-CAAAGAGACCTACGTCGAGC-3’ and
REV 5’-TTTGGGGGTGAGGCATTAAC-3’ primers. The PCR cycling program was as
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follows: 95°C 5 min, 95°C 30 sec (decrease 0.5°C every cycle) and 68°C 1.5 min for 15
cycles, 95°C 30s 58°C 30s and 72°C 1.5 min for 20 cycles, last extension for 5 min at
72°C. PCR products were run on a 1% TAE agarose gel at 100 v for 40 min, and imaged
with Image Quant LAS 4000 (GE) (Figure 3-3, B).
3.2.6. Fluorescence-activated cell sorting (FACS)
PCa cells, 72 hrs post transfection with ZFNs+donor and donor-only, were
trypsinized and dissociated into 5x105cells/ml in 1xPBS. Generally, 1~2x106 cells were
used for FACS. To eliminate dead cells, we stained the single-cell suspension with
eFluor506 viability dye (eBioscience, 65086614) for 30 min at 4°C per manufacture’s
instructions. The tagRFP was excited with the 555 nm laser and analyzed at 584 nm.
The viability fluorescence eFluor506 was excited at 405 nm laser and analyzed at 506
nm.
3.2.7. LNCaP conditioned media collection
LNCaP cells were cultured in RPMI supplemented with 10%FBS. Once at 70%
confluence, media was aspirated and cells were rinsed three times with sterile 1xPBS,
and three times with serum-free RPMI. After cells were incubated in 50 ml serum-free
RPMI for 48 hrs, the conditioned media was removed and filtered with a 0.45-micron
filter. A 1:1 ratio of conditioned media to normal growth media was then subsequently
used to culture single LNCaP cells.
3.2.8. LNCaP single-cell clonal culture
The RFP+ LNCaP cells sorted from the ZFN and donor co-transfected group, were
cultured for one week, and then trypsinized and seeded into 96-well plates at a ratio of 1
cell per 200 µL of media per well. After 5 hrs, fluorescence microscope was used to scan
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all wells, and wells containing a single RFP+ cell were marked. Single LNCaP clones
were identified after three weeks, and were passed into 24-well plates. Approximately
half of the cells at the 24-well stage were stored in liquid nitrogen.
3.2.9. Genotyping
Genomic DNA was isolated from RFP clonal cells using the QiAamp DNA Mini Kit.
Two sets of primers were used for genotyping these clones including: P1 flanking the
ZFN

cutting

site

FWD:

5’-GAAGGGGGAGGAAACAAAAG-3’

and

REV:

5’-

TAGAGGAAATTCCCCAAGGC-3’, and P2, which were designed inside the transgene
tagRFP,

FWD:

5’-ACTTCAAGTGCACATCCGAGG-3’

AGTTTGCTAGGGAGGTCGC-3’.
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and

REV:

5’-

Figure 3-3 Cel-1 assay and junction PCR
A. The Cel-1 assay was used to estimate the cutting efficiency of ZFNs in targeted
region. The region of interest was amplified, denatured and then the PCR products were
re-annealed. The alleles with mismatches can be annealed with wild-type alleles, and
form mismatch loops. Using the SURVEYOR enzyme, which can recognize and digest
the mismatch loops, appearance of the two lower bands on gel compared to the negative
control indicates DSBs and ZFN cutting efficiency.
B. Junction PCR was used to predict the possibility of integration using genomic DNA.
We designed primers flanking 5’ and 3’ HRs, and only the genomic DNA containing
integrated region should show a positive band. Donor-plasmid-only transfected cells
were used as negative control.
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3.3.

Results

3.3.1. Design an AR tracking model in PCa cells with ZFNs
In this section, our goal was to generate AR-tagged PCa cell line models, in which
a reporter gene was knocked into the C-terminus of AR under the control of endogenous
promoter. The workflow and overall strategy are shown in Figure 3-4 and Figure 3-5.
First, among the four commonly used human PCa cell lines, LAPC9, LAPC4, PC3 and
LNCaP, we discovered a ~100 bp consensus region upstream of the AR stop codon
(Figure 3-6). In this region, sixteen ZFN candidates were identified and three of them
were selected for further studies including ZFN14, which displayed the highest cutting
efficiency, and ZFN1 and ZFN3, which were closer to the stop codon (Figure 3-7).
Meanwhile, donor constructs containing the reporter tagRFP were designed for the HDR
(Figure 3-8). The 2A peptide was used to link AR and tagRFP, based on the observation
that not only can 2A peptide divide the two proteins during translation, but their
expression levels were highly coordinated as well [103]. The P2A peptide
(ATNFSLLKQAGDVEENPGP) was used in the final donor construct, which produces the
highest cleavage rates in multiple human cancer cell lines [104]. Further, the P2A
peptides have been optimized for transgene expression by adding furin cleavage site
(RAKR) and spacer (SV-SGSG) peptides [105]. Furin is a ubiquitously expressed
endoprotease and cleaves many precursor proteins at specific internal peptide bonds in
the trans-Golgi network. This design allows furin to cut off the 2A resides, leaving a
minimum attachment (RAKR) to AR. To test the reporting efficiency of the transgene in
PCa cells, the transgene was inserted into the C terminal of pEGFP-C2 (Clontech, CA)
(Figure 3-8, upper panels). At 72 hours post transfection (5 µg), we observed a highly
coordinated expression of eGFP and tagRFP in LNCaP cells (Figure 3-8, lower).
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Figure 3-4 workflow of generating AR-tagging clones with ZFNs.
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Figure 3-5 AR tagging strategy
ZFN14 pair (ACCTGCTAATTAATCAAGTCACnnATGGTGAGCGTGGACTTTCC
G) was designed to induce DSB at the 3’ of AR gene before the stop codon TGA. Donor
vector contains the sequences of furin binding peptide, P2A peptide and tagRFP cDNA.
This backbone was flanked with 800 bp homologous arms on each side, which are the
sequences immediately upstream and downstream of AR stop codon. With HDR, the
transgenes were inserted into AR gene before TGA.
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Figure 3-6 Consensus sequence at the AR C terminal region in 4 human PCa cell
lines.
Alignment of the AR C-terminal sequence in cultured LAPC9, LAPC4, PC3 and
LNCaP cells with the hAR sequence (NC_000023.11) at GeneBank. The sequence
between the T877A mutation (red) in LNCaP cells and the stop codon (TGA; highlighted
in yellow) was conserved among the four PCa cell lines.
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Figure 3-7 ZFN candidates for AR targeting
Shown are the 16 ZFN candidates (cand 1- cand 16) located about 130 bp
upstream of the AR C-terminal stop codon (TGA; boxed). ZFN candidate 14, 3 and 1
were synthesized and used in this study.
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Figure 3-8 Donor plasmid verification
The transgenes in the donor construct were inserted into pEGFP-C2 (Clontech,
CA) following eGFP (upper panel). Representative images of LNCaP cells 72 hrs post
transfection with the GFP-RFP fusion protein (lower panel).
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3.3.2. ZFN14-meditated AR tagging in K562 cells
We initially utilized K562 cells for optimizing the experimental setting. The K562
cell line is a human erythromyeloblastoid leukemia cell line, derived from a 53-year-old
female chronic myeloid leukemia patient in blast crisis [106]. In comparison to the
majority of PCa cell lines, K562 cells have a higher proliferation rate and are easier to
manipulate. Importantly, K562 cells express low levels of AR. In an effort to identify the
most efficient method to deliver ZFN pairs, lipid-based transfection, Nucleofection™, and
electroporation at different voltage (v) and capacitance (µF) (i.e., 200 v/125 µF, 200
v/150 µF, 250 v/150 uF and 300 v/125 µF), were tested and compared. Results showed
that Nucleofection™ with ZFN14 yielded the highest cutting efficiency, as 51% of the
tested cells were cut (Figure 3-9). Co-transfection of ZFN14 and the donor construct with
Nucleofection™ in K562 cells generated ~14% RFP+ cells (Figure 3-10, A and C). The
positive junction PCR band confirmed integration in the co-transfected group (Figure 310, B). These results suggest that this system works well in cancer cells.
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Figure 3-9 Cutting efficiency of ZFN14 in K562 cells
A. Results from the K562 Cel-1 assay. Cells were transfected with 5 ug ZFN14 pairs
using the following electroporation conditions: 200 v/125 µF, 200 v/150 µF, 250 v/150 uF
and 300 v/125 µF. Red arrows indicate DSBs induced cut bands.
B. Cel-1 assay results in K562 cells transfected with ZFN14 using three transfection
methods: electroporation (200 v/150 µF), Lipofectamine 2000, and Nucleofection (T016). Red arrows indicate DSBs induced cut bands.
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Figure 3-10 AR tagging system in K562 cells
A. Representative images of K562 cells transfected via three different transfection
methods: 5 µg pEGFP (upper row), ZFN14 and Donor1 (D1) plasmid (middle row),
Donor1 only (lower row). Shown on the left are phase images, and on the right are darkfield fluorescence images.
B. Gel image of the 5’ and 3’ junction PCR results. Z14: ZFN14-only transfection, Z14D1:
ZFN14 and donor 1 co-transfection, and D1: Donor1-only transfection. Expected PCR
product of 5’ junction is 890 bp and of 3’ junction is 1020 bp.
C. FACS plots of K562 cells. Annexin V and eFluor506 were used to screen for live cells.
RFP+ cells represent 14% of the total in the co-transfected group, compared to the D1
only group.
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3.3.3. ZFN14-meditated AR tagging in LNCaP cells
As LNCaP cells displayed heterogeneous AR expression, our next goal was to
select for clonal AR-positive LNCaP cells using the ZFN-KI system.
To deliver ZFN pairs to LNCaP cells, we found that the Nucleofection™ method
was again the most efficient, introducing DSBs in approximately 62.5% of the cells
(Figure 3-11). In this protocol, Lipofectamine 2000® was used for the ZFN and donor
cotransfection, which increased cell survival. Two additional ZFN pairs, ZFN1 and ZFN3
(Figure 3-12, A), were also tested based on their closer proximity to the integration site
and the propensity of such ZFNs to yield higher homologous recombination rates [107].
Meanwhile, two additional donor plasmids with differing lengths in the homologous arms
were also made providing more options. Donor2 (D2) contains two shorter HRs (300 bp
and 136 bp) and Donor3 (D3) contains longer 5’ and 3’ HRs that are 2 kb each (Figure 312, B).
Among the three ZFN pairs tested, ZFN14 was the most efficient yielding 38% of
the total DSBs in LNCaP cells, whereas ZFN1 and ZFN3 pairs introduced DSBs in
approximately 10% cells (Figure 3-13, A). We didn’t observe a significant increase in
efficiency when cells were cultured at 30°C (Figure 3-13, A). Additionally, the ZFN
plasmid was more efficient than the ZFN14 mRNA (Figure 3-13, C).
Comparing all different combinations of ZFNs and donors, only the group
cotransfected with ZFN14 and the original donor (Donor1) produced positive bands in
both 5’ and 3’ junction PCRs (Figure 3-13, B and C), suggesting possible integration at
the target site with the ZFN14/D1 combination. Approximately 1% of the RFP+ cells with
this combination could be identified and sorted out for single cell expansion (Figure 3-13,
D). Culturing these LNCaP cells in different conditions (i.e., RPMI + 15% FBS; 10%
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Matrigel + RPMI + 15% FBS; RPMI + 15% FBS + 10 nM DHT; or RPMI + 15% FBS +
EGF/FGF) proved extremely difficult due to their fragile nature. However, culturing single
sorted cells in LNCaP-conditioned media [108] allowed us to successfully establish 46
RFP+ LNCaP clones. Two sets of primers, P1 flanking the sequences around the ZFN
cutting sides and P2 inside the tagRFP gene (Figure 3-14, A), were used for genotyping.
All of the 46 clones harbored one larger allele and one short wild type allele (Figure 3-14,
B). All six clones we tested (including Clone 19, 30 and 31) also had positive RFP bands
with P2 amplification (Figure 3-14, B). Sequencing of the upper bands indicated
successful integration of the transgenes (Figure 3-14, C). We name the tagged clones as
AR-clone number, such as AR-30.
We characterized two AR-tagged clones AR-30 and AR-31 first by AR IF staining.
We observed homogeneous AR+ expression in both clones, compared to 60-70% of
AR+/hi cells in bulk LNCaP cell culture (Figure 3-15, A). And the AR-tagged clones were
highly RFP+ under the fluorescent microscope (Figure 3-15, B). Further, by western
blotting with AR and tagRFP antibodies, we demonstrated that AR protein in the tagged
clones has the same molecular weight 110 kDa as that in the wild type LNCaP cells
(Figure 3-15, C). Using tagRFP antibody, we did not detect any AR signal in the tagged
clones AR-30 and AR-31 (Figure 3-15, D). The data suggests that tagRFP was fully
cleaved from AR protein in the tagged clones by P2A peptide and furin binding site.
We also verified the correlation between RFP expression and endogenous AR
protein level. We observed a loss in RFP+ cells 72 hrs post AR siRNA treatment (Figure
3-16, A). FACS analysis confirmed this by revealing that the RFP+ population decreased
from 60.1% to 30.2% (Figure 3-16, B). This experiment suggested that the RFP faithfully
reported endogenous AR expression in LNCaP cells. Four RFP-tagged AR+ LNCaP
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clones: AR-12, AR-19, AR-30 and AR-31 were utilized in the further studies, which were
discussed in Chapter 5.
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Figure 3-11 Cutting efficiency of ZFN14 in LNCaP cells
Cel-1 assay results of LNCaP cells transfected with 5 µg ZFN14 pairs using three
methods: Lipofectamine 2000®, electroporation (200 v/150 µf) and Nucleofection (T-009).
Red arrows indicate lower bands cut by ZFNs. The highest cutting efficiency (62.5%)
was yielded 48 hrs post Nucleofection.
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Figure 3-12 Alternative ZFNs and donor plasmid modifications
A. Additional ZFNs. ZFN1 cuts at one nucleotide before the AR stop codon TGA. ZFN3
cuts at eight nucleotides before the AR stop codon. A red “n” indicates cutting sites.
B. Two modifications were made to the original donor plasmid (Donor1) including: two
shorter HRs, 300bp and 136bp (Donor 2), and longer 5’ and 3’ HRs that are each 2kb
(Donor 3).
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Figure 3-13 The AR tagging system in LNCaP cells
A. Cel-1 assay results. Nucleofection (T-009) was used to deliver 5 µg of ZFN pairs 1, 3,
or 14 d into LNCaP cells. One group of cells was cultured at 30°C to induce a cold shock
after the transfection and is indicated as cZ14, cZ1 and cZ3. Red arrows indicate bands
cut by ZFNs. +/-: Cel-1 assay positive and negative control.
B. The 5’ and 3’ junction PCR results of co-transfected cells. Donor1-only (D1) was used
as the negative control. Z1D1, Z1D2, Z3D1 and Z14D1 are different combinations of
ZFN1, ZFN3, ZFN14 and Donor plasmids Donor 1 and donor 2. Expected PCR product
of 5’ junction is 890 bp and of 3’ junction is 1020 bp.
C. Cel-1 assay and junction PCR results using mRNA and DNA from ZFN14. ZFN14
mRNA was shown to be less efficient in inducing DSBs (red arrows) with Cel-1 assay
(Left panel) and homologous integration (red arrows) by junction PCR (Right panel)
compared to ZFN14 plasmid.
D. Gating strategy and FACS analysis of tagRFP in LNCaP cells 72hrs post cotransfection of ZFN14 and Donor1. LNCaP cells were stained with Annexin V and
eFluor506 to select for live cells. In the examples shown, the RFP+ population in the cotransfected group represented 1.37% of the total population, and in the donor-only group
RFP+ cells represented 0.08%.
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Figure 3-14 Genotyping of the RFP clones
A. Primers used in the RFP+ clones genotyping (left panel). P1 and P2 represent the 2
pairs of primers. F, forward; R, reverse.
B. Representative gel images of PCR data utilizing primer 1 (P1) and primer 2 (P2) (right
panel). With P1, the upper bands 1174 bp represent the integrated allele and the 400 bp
bands the wild type band. With P2, the positive 614 bp bands represent the tagRFP
sequences.
C. BLAST results of the RFP clones and wild type AR. The first line represents the wild
type AR C-terminus sequence. The second line represents the donor plasmid sequence.
The remaining sequences are from clones 30 and 31. The green bar indicates the furin
binding peptides, the yellow bar indicates 2A peptides, and the red bar indicates the tagRFP sequences.
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Figure 3-15 Characterizations of the AR-tagged clones
A. AR-tagged clones are homogeneously AR+. Representative images of AR IF staining
in two AR-tagged clonal cells (AR-30 and AR-31), and in bulk LNCaP cell cultures, in
which AR expression is apparently heterogeneous. Scale bar: 20 µm
B. AR-tagged clones are RFP+. Live cell images of both phase and dark field of ARtagging cells and bulk LNCaP cells. Scale bar: 200 µm
C-D. tagRFP was fully cleaved from AR at the protein level. Western blot analysis of AR
(C) and tagRFP (D) protein levels in AR-30, AR-31 and bulk LNCaP cells. Short time
exposure films are on the left sides, and longer time exposure films are on the right
sides. β actin was probed as an internal loading control.
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Figure 3-16 AR siRNA knockdown in RFP+ clones
A. Representative images of two groups of AR-30 cells treated with AR siRNA or
negative control (NC) siRNA. The RFP signal is lost in cells treated from day 1 to day 3
with AR siRNA. (Scale bar 20 µm)
B. FACS analysis showing the knockdown effect of AR siAR on RFP expression
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3.3.4. ZFN14-meditated AR tagging in PC3 cells
The AR-negative PC3 cell line model was used as the negative control. Among
the three transfection methods, Nucleofection™ was again the most efficient resulting in
DSBs in 37% of PC3 cells (Fig 3-17, A). Junction PCR results suggested positive
integration at the target site (Fig 3-17, C). However, no RFP+ cells were observed upon
ZFN14 and D1 cotransfection, supporting the specificity of the tagRFP reporting system.
(Fig 3-17, B and D)
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Figure 3-17 The AR tagging system in PC3 cells
A. Cel-1 assay results for PC3 cells. Three groups of PC3 cells 48 hrs post the
transfection with 5 µg ZFN14 by Lipofectamine 2000® (lipo), electroporation (elec) and
Nucleofection (nucle) are reported. UC represents PC3 cells transfected with 5 µg GFP.
B. Representative images of cells infected with the indicated plasmids.
C. The 5’ and 3’ junction PCR results. Expected PCR product of 5’ junction is 890 bp and
of 3’ junction is 1020 bp.
D. FACS analysis plots of PC3 cells subjected to either Donor1 only or ZFN14 and
Donor1 co-transfection.
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3.4.

Discussion
In this part of the project, we have successfully designed a genetic strategy to

knock in a fluorescent reporter into the endogenous AR locus using ZFN-induced DNA
DSBs and a donor plasmid template (Figure 3-5). In brief, we inserted tagRFP in-frame
with the endogenous AR gene and selected individual LNCaP clonal cell lines, which
were verified by sequencing. Although the applications of ZFNs, TALENs and
CRISPR/Cas9 technologies have been shown to improve the HDR efficiency, knock-in of
large DNAs with HDR-mediated integrations in cancer cells has proven to be extremely
difficult. Many of the experimental parameters influencing the efficiency of genome
editing need to be finely tuned to achieve a decent integration rate. In our case, we
tested three ZFN pairs with various distances to the insertion site, to induce DSBs
(Figure 3-7), and we delivered both DNA and mRNA forms of ZFN pairs using three
different methods (Figure 3-9, 3-11 and 3-13). Further, we flanked the transgene with
three versions of HR arms (~200 bp, 800 bp and 2 kb) (Figure 3-12). With multiple
combinations, the ZFN14 in combination with the donor that is flanked with 800 bp HR
arm on each side is identified as the most efficient method for AR-tagging integration in
LNCaP cells (Figure 3-13). In an effort to avoid the negative effects induced by antibiotic
screening on LNCaP cells, we designed the donor structure in the way that the
fluorescent reporter gene can be used as a positive integration-screening marker. This
allowed rapid assessment of both an accurate knockin rate and quantification of AR+
LNCaP cells via FACS analysis. To evaluate false-positive effects, such as RFP
expression from the donor without integration, all of our experiments include a donoronly transfection. Also, to minimize potential side effects induced by the AR-RFP fusion
protein, we inserted both furin cleavage site and P2A peptide before the reporter gene.
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This model was first tested in pEGFP-C2 vector, which revealed that both GFP and RFP
were expressed simultaneously (Fig 3-8).
On the other hand, due to the fragile and slow growing nature of LNCaP cells,
after multiple steps of manipulation, very few single LNCaP cells survived the selection
process. This LNCap cell attribute has prevented many scientists in the PCa field from
generating isogenic LNCaP clonal cell lines. In this study, however, after designing and
modifying multiple culture media, we successfully identified an LNCaP conditioned media
ideal for culturing and expanding LNCaP clones.
In conclusion, we have successfully developed a genetic protocol to precisely tag
the endogenous AR in cancer cells, which includes ZFN binding site selection, DNA
donor design, transfection optimization, time point assessment, single cell culturing, and
detection of successful integration. This research not only has allowed the establishment
of novel AR-tagged LNCaP clonal models, but has also provided great potential in
developing similar tagging models in other PCa cell lines (LAPC9, LAPC4, etc) as well
as in primary human PCa cells. Further, the strategies described here should be
applicable to other HDR-mediated insertion of large DNA fragments into different
genomic locations in PCa cells.
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Chapter 4. Generate AR Knockout (KO) PCa cell
clones using CRISPR-cas9 technique
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4.1.

Introduction
The RNA-guided CRISPR-Cas9 gene-editing tool relies on the cas9 nuclease

guided by small RNA through Watson-Crick base pairing with target DNA, and has
proven to be efficacious in virtually all cell types [109, 110] (Figure 4-1). In an effort to
establish roles for AR in a defined context, we employed the CRISPR-cas9 system to
selectively knock out full-length AR in LNCaP cells. Two independent sgRNAs that target
the 5’ of AR gene produced null deletions in six single cell clones. These AR-KO (AR
knock-out) clonal LNCaP cells did not express AR at both mRNA and protein levels,
exhibited reduced to undetectable expression of AR downstream target genes such as
PSA, TMPRSS2 and NKX3.1, and showed significantly lower responses to androgens
compared to the AR-tagging clones. Collectively, our data supports the use of this
powerful and accessible gene-editing technology in successfully establishing isogenic
knockouts in PCa cells allowing elucidation of specific gene functions.
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Figure 4-1 Schematic of the RNA-guided Cas9 nuclease
The cas9 nuclease from S. pyogenes is targeted to ‘Gene of Interest’ by a gRNA
consisting of a 20-nt guide sequence (blue bar) and a scaffold (red). The guide sequence
pairs with the DNA target (blue bar) upstream of a 5’-NGG adjacent PAM motif (pink).
Cas9 then introduces a DSB ~3 bp upstream of the PAM.
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4.2.

Materials and methods

4.2.1. sgRNA design and CRISPR nuclease assembly
Two gRNAs, gRNA1 and gRNA2 (Figure 4-2, B) were designed targeting the AR
exon 1 using the following website: http://crispr.mit.edu. The gRNAs scores (59 and 97,
respectively) were decent and predicted limited cleavage potential at off-target sites. We
designed single-stranded DNA oligonucleotides, annealed into double-stranded DNA
oligonucleotides and cloned them into the CRISPR nuclease vector (A21174,
ThermoFisher) (Figure 4-3, A). In the CRISPR nuclease vector, human U6 promoter
drives the gRNA expression, and the CMV promoter drives the cas9 nuclease
expression (Figure 4-3, A). The reporter gene, OFP (orange fluorescence protein)
(Figure 4-3, A) following the cas9 nuclease was used to screen for the transfected cells
via FACS analysis.
4.2.2. Fluorescence-activated cell sorting (FACS)
LNCaP cells were trypsinized and resuspended at a 5 X 105/ml single cell
concentration in 1xPBS, 72 hrs post CRISPR plasmid transfection. Approximately
1~2x106 cells were utilized for FACS analysis. Propidium iodide was used to eliminate
dead cells. OFP was excited with a 555 nm laser and analyzed at 584 nm. In order to
enrich for cells that received high levels of the CRISPR-cas9 plasmid, we focused only
on the top ~2% OFP-positive cells.
4.2.3. IF Microscopy
Single clonal cells were placed on poly-lysine-coated glass coverslips and
incubated with mouse monoclonal anti-AR (N20, SC-816, Santa Cruz Technology;
1:200) diluted in 1xPBS containing 0.1% Triton and 5% goat serum for 2 hrs at RT. After
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thorough washing, the coverslips were incubated for 60 min with Alexa Flour 488conjugated goat anti-Rabit IgG secondary antibody (Invitrogen) (1:1000) in 1xPBS plus
0.1% Triton and 5% serum. After thorough washing, cells were stained with DAPI (H1200; Vector Laboratories, Burlingame, CA) for 10 min at RT and the coverslips were
mounted with 6 µL ProLong® Gold anti-fade reagent (Invitrogen). Images were acquired
within 30 min on an Olympus microscope.
4.2.4. Genotyping
Genomic DNA was isolated from AR-KO clonal cells using the QiAamp DNA Mini
Kit.

Primers

used

for

sequencing

included

ARN

FWD:

5’-

GAGACAGACTGTGAGCCTAGC-3’ and ARN REV: 5’-GCTGTGAAGGTTGCTGTTCC3’.
4.2.5. Western blotting antibodies
Antibodies used in Western blotting included: anti-AR (N20, SC-816, Santa Cruz,
1:1000), anti-AR (ab74272, abcam, 1:1000, aa180-320), anti-PSA (C-19 SC-7638, Santa
Cruz, 1:1000), anti-NKX3.1 (SAB2101603, Sigma, 1:1000), anti-TMPRSS2 (ST1676,
Calbiochem, 1:500), anti-β actin (ab8227, Abcam, 1:2000)
4.2.6. qRT-PCR primers
Total RNA was extracted using RNeasy Mini Kit (Qiagen) according to the
manufacturer’s instructions. qRT-PCR was performed using an CFX Connect Real-Time
PCR Detection System (Bio-Rad). qPCR data were normalized to 18S. Primer
information was listed as follows. 18S: FWD: 5’-AAGTCCCTGCCCTTTGTACACA-3’
REV:

5’-GATCCGAGGGCCTCACTAAAC-3’
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AR:

FWD:

5’-

TAGGGCTGGGAAGGGTCTAC-3’ REV: 5’-GGGAGGTGCTGCGCTC-3’. PSA FWD: 5’GATGAAACAGGCTGTGCCG-3’ REV: 5’-CCTCACAGCTACCCACTGCA-3’.
4.2.7. Luciferase assay
LNCaP clonal cells were seeded in 24-well plates (3x104 cells/well) and were cotransfected with 1 µg ARE or PSA reporters together with the Renilla luciferase internal
normalization plasmid (phRL-CMV). As a control, one group was treated with 10 nM
DHT, 12 hrs before measuring luciferase activities. The ratio of firefly to Renilla
luciferase activity was determined with a dual luciferase assay (Promega) 48 hrs later.
Unpaired two-tailed Studentʼs t-test was used to compare differences between groups,
and P < 0.05 was considered statistically significant.
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4.3.

Results

4.3.1. Design efficient gRNAs to target human AR in LNCaP cells
The workflow depicting the generation of CRISPR-cas9 knockout cell lines is
shown in Figure 4-2 A. The specificity of the cas9 nuclease is determined by the 20-nt
within the sgRNA and the target sequence must be 5’ to a NGG PAM sequence. Based
on these specifications, it was imperative to identify 5’-NGG and to minimize the offtarget effects when selecting guide sequences for gene targeting. We also had to keep in
mind that DSBs at the 5’ end of the gene tend to have a greater possibility of inducing
frame shift mutations that may disrupt the whole gene. Additionally, it has been
demonstrated that targeting functional protein domains substantially increases the
efficiency of generating null mutations [111]. The NTD of AR is a critical domain that
governs the transcriptional function [1], thus making the 5’ end an ideal locus to target.
Complying with these basic principles, we submitted the -20 bp to +150 bp sequence of
AR gene to the http://crispr.mit.edu website for gRNA scanning. The two gRNAs used in
this study, gRNA1 and gRNA2, are predicted to target the AR gene a short distance from
the start codon (Figure 4-2, B). We cloned the 2 gRNAs into a vector containing both
gRNA insertion sites and the cas9 expression cassette (Figure 4-3, A). The OFP in the
vector enabled screening of cas9 expressing cells (Figure 4-3, B). Both plasmids with
gRNA1 and gRNA2 were transfected into LNCaP cells with Lipofectamine 2000. The top
2% OFP+ cells were FACS sorted 72 hrs post transfection (Figure 4-3, B). We observed
mutually exclusive expression patterns between AR and OFP via IF staining (Figure 4-3,
C), indicating efficient elimination of AR by transient transfection of cas9 protein and the
gRNAs.
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Figure 4-2 General strategies to generate AR-KO LNCaP clones using the CRISPRcas9 system
A. Workflow of the experiments
B. Schematic depicting the two sgRNAs targeting at the 5’ of human AR gene. gRNA1
(blue bar) targeted 11 bp downstream from the start codon ATG (green arrowhead)
whereas gRNA2 (blue bar) targeted 86 bp away from the ATG (green arrow head). Note
the gRNA2 is reverse complementary to the target sequence.
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Figure 4-3 AR-KO with CRISPR-cas9 in bulk LNCaP cells
A. The GeneArt ® CRISPR Nuclease Vector map. The vector (Life technologies)
contains human U6 promoter that drives gRNA expression, CMV promoter that drive
cas9 expression, and 2A peptide that mediates OFP/CD4 expression as cas9 reporter.
The OFP vector is linearized at nucleotides 6732 and 6752 with 5 base pair 3’ overhangs
on each strand as indicated.
B. LNCaP cells transfected with CRISPR-cas9 plasmids containing gRNA1 and gRNA2
were FACS sorted 72 hrs post transfection. Cells of the top 2% were collected for single
cell cloning.
C. OFP+ cells of the top 2% displayed mutually exclusive expression patterns of AR and
OFP as revealed by IF staining. OFP- cells showed similar AR expression patterns
compared to bulk LNCaP cells (top row). The majority of OPF+ cells did not express AR
(bottom row).
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4.3.2. Establish AR-KO LNCaP cell clones
Use of the CRISPR-cas9 knockout system enabled the successful generation of
AR knockout LNCaP cell lines. Next, single OFPhi LNCaP cells were resuspended in
LNCaP conditioned media and seeded into 96-well plates in an effort to support clonal
growth. After six weeks, 35 clones were collected and six were identified as
homogeneous AR- clones, we name the clones as KO-01, KO-03, KO-14, KO-16, KO-21
and KO-41 (Figure 4-4, A). CTRL-12 was selected as a negative control, which
originated from an OFP+ cell but displayed AR positive expression. These six clones
were further probed with two additional AR antibodies producing similar results to IF
staining (Figure 4-4, B).
To identify specific modifications induced by the DSBs in the six clones, we
amplified the 5’ region of the AR gene (Figure, 4-5, A) with the six clones. Based on the
gel image (Figure 4-5, B), we proposed that KO-14 and KO-41 possessed two different
modifications on the two alleles, one with large insertions, and the other may have
harbored minor changes undetectable on the gel. The other AR-KO clones may also
have had minor deletions or indels in the genome, which produced the AR null
phenotype. By sequencing the PCR products, the mutations in the clones were identified:
KO-01 had +3 bp and -75 bp mutations, KO-03 had -90 bp and -75 bp mutations, KO-14
had -75 bp and +284 bp mutations, KO-16 was homozygous with -75 bp deletions in
both alleles, KO-21 had -5 bp and -75 bp deletions, and clone 41 had -75 bp and + 520
bp mutations around the two sgRNA directed sites (Figure 4-5, C).
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Figure 4-4 Screening of AR-KO clones
A. Clones (35 total) derived from the OFP+ LNCaP cells were screened based on AR
expression (PG-21, 1:200) via IF staining. KO-01, KO-03, KO-14, KO-16, KO-21 and KI41 clones displayed the AR-knockout phenotype. In contrast, other clones such as
CTRL-12, originally also derived from OFP+ cells, were heterogeneously AR+.
B. The lack of AR protein in the six clones was further confirmed via Western blotting
using two additional AR antibodies: N-20 (1:1000) and ab74272 (1:1000).
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Figure 4-5 Genotype of the AR-KO clones
A. Primers used to amplify the targeted region (ARN FWD and REV).
B. Genotyping of the AR-KO clones. Genomic DNA extracted from the indicated clones
was amplified with ARN primers. KO-01, KO-03, KO-16 and KO-21 clones showed minor
changes in the genome that cannot be deciphered on a gel. One allele of KO-14 and
KO-41 harbored large insertions (284 bp and 520 bp, respectively), and the other allele
may have small modifications. KO-12 was used as negative (non-targeted) control.
C. BLAST results of the six AR-KO clones. Mutations are shown in red. gRNAs and PAM
sequences were indicated as blue and pink bars. The 2 alleles in the six clones
contained different mutations, indicated on the left. Clone 16 had the same deletions in
both alleles.
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4.3.3. Characterize AR functions in the AR-KO clones
AR is paramount for the prostate lineage-specific differentiation, and it maintains
the differentiated state of prostate epithelium via regulation of prostate-specific genes
such as PSA, TMPRSS2 [112] and NKX3.1 [113]. To test AR activity in the AR-tagging
and AR-KO LNCaP cells, downstream target genes were analyzed via Western blot and
qRT-PCR analysis comparing to two RFP-tagged AR+ LNCaP clones. PSA was
undetectable in KO-03 and KO-16 cells at both the mRNA and protein levels (Figure, 46). TMPRSS2 and NKX3.1 expression were significantly reduced in the KO clones
compared to AR+ clones (Figure 4-6, A). To test the canonical ligand-induced AR activity,
ARE and PSA luciferase assays were performed in AR-KO and AR+ cells with and
without 10 nM DHT treatment. A significantly lower baseline activity and extremely low
response to androgen stimulation were observed in the AR-KO cells compared to AR+
cells. Collectively, our data demonstrated undetectable AR mRNA and protein
expression, low canonical AR signaling, and blunted androgen responses in AR-KO cells.
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Figure 4-6 Attenuated AR signaling in AR-KO clones
A. Western blot analysis of AR, TMPRSS2, NKX3.1 and PSA protein expression in AR30, AR-31, KO-03 and KO-16 clones. Indicated below are relative expression levels as
determined by densitometric scanning of the individual bands and normalized to
respective β actin and compared to the protein levels in AR-30.
B. qPCR analysis of AR and PSA mRNA levels in AR-30, AR-31, KO-03 and KO-16
clones. Values represent mean ± s.e.m. of triplicates from three independent
experiments, and were normalized to the levels in clone AR-30.
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Figure 4-7 Lower AR activity and blunted DHT responses in AR-KO cells.
Presented are results of ARE (A) and PSA (B) Luciferase reporter assays in AR-30, AR31, KO-03 and KO-16 clonal cells with and without 10 nM dihydrotestosterone (DHT)
treatment. Values represent mean ± s.e.m. of triplicates from three to five independent
experiments. P values were determined using unpaired student's t-test.
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4.4.

Discussion
Prostate-specific deletions of AR in mice resulted in increased proliferation and

less differentiated epithelium [28, 29]. However, silencing AR with small-interfering RNA
[114] or short-haripin RNA [72] in human PCa cell lines (LNCaP and C4-2 cells)
suggested an oncogenic role for AR. The major concern with the study [71, 72] is the
heterogeneous AR knockdown effect on AR+ and AR-/lo cells that co-exist in LNCaP and
C4-2 cells. The effects from dominant subpopulation may provide misleading results. In
order to overcome this issue and establish accurate roles for AR in human PCa cells,
establishment of a defined context is fundamental.
Herein, we have outlined our approach to selectively knock out full-length AR in
LNCaP cells using the CRISPR-cas9 system and the subsequent successful derivation
of isogenic AR-KO clones. We chose a CRISPR-Cas9 construct that harbors an OFP
expression cassette in order to observe transfection efficiency and to enable cell sorting
for enrichment of deletion alleles. Two adjacent but independent sgRNAs were designed
to help control for inefficient sgRNA and maximize clones with biallelic deletions. The
commonly observed outcomes included small deletions at the cas9 cleavage sites and
bulk deletions between the two sgRNA sites. Two large insertions in KO-14 and KO-41,
and between the two cutting sites were mapped to the CRISPR-cas9 vector sequence.
Notably, clones with both in-frame and frameshift mutations displayed indistinguishable
AR negativity, suggesting that both mutational classes were genetic nulls. These results
could be ascribed to the critical role of the AR NTD. Similar functionally defective inframe mutations have been observed in other genes. For example, Shi et. al. [111]
showed, via deep sequencing, that in-frame deletion in BD1 domain of Brd4 gene,
ATPase domain in Smaraca4 gene, methyltransferase domain in Ezh2 and Dot1l genes
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all contribute to null mutations. In our studies, to further minimize the CRISPR-Cas9 offtarget effects [115], six AR-KO clones were generated and three (KO-01, KO-03 and KO16) were utilized in subsequent functional studies.
In summary, we have successfully generated novel isogenic AR-KO LNCaP cell
clones utilizing CRISPR-Cas9 system. These AR-KO clones do not express AR at both
the mRNA and protein levels (Figure, 4-6). Also, the AR activity in these clones is
significantly dampened as evidenced by reduced responses to androgen stimulation
(Figure 4-7) and much reduced expression of downstream target genes including PSA,
TMPRSS2 and NKX3.1, compared to the RFP-tagged AR+ clones (Figure, 4-6, A).
Importantly, this study has provided practical guidelines for harnessing CRISPR-Cas9
system in PCa cells, a technique that can be shared potentiating collective advances in
the PCa field.
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Chapter 5. Functional and molecular studies in
isogenic AR+ and AR-KO LNCaP cells
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5.1.

Introduction
The current mainstay clinical treatment for advanced PCa includes ADT

compounds such as traditional antiandrogens and second generation AR antagonists
such as enzalutamide and abiraterone. Unfortunately, the inevitable failure of ADT
results in the progression to CRPC. The exact mechanisms underlying the switch from
androgen-dependent PCa to CRPC are incompletely understood and thus, metastatic
CRPC remains incurable. Identification and characterization of PCa cell targets may
potentially lead to new multi-pronged therapeutic approaches to successfully eliminate
CRPC cells. In previous studies, we reported that PSA-/lo PCa cells possess long-term
tumor propagating properties, and can initiate robust tumor regeneration in fully
castrated hosts [7]. Further, we showed discordant mRNA and protein expression
patterns between AR and PSA in all stages of PCa (Figure 1-4 and 1-5). In addition,
different patterns of AR expression were shown in CRPCs: AR-/lo, AR+/hi and cytoplasmic
AR (Figure 1-6). These results suggest that AR signaling as well as AR-independent
signaling pathways are involved in CRPC progression. The goal of this study is to
elucidate how this AR heterogeneity may impact PCa biology and response to clinical
treatments.
Using our isogenic AR+ and AR- LNCaP cells, we performed systematic analysis
to compare the intrinsic biological properties and tumor regenerating capabilities of the
two subpopulations in both androgen dependent (AD) and androgen independent (AI)
environments. Our data showed highly distinct and context dependent tumor
regenerating abilities in both subpopulations. In terms of therapeutic resistance, AR- cells
demonstrated higher resistance to enzalutamide treatment compared to AR+ cells. Taken
together, these studies link AR heterogeneity to distinct androgen environment and
108

castration/enzalutamide responses, and provided evidence for a more efficacious
therapeutic strategy that targets AR-/lo PCa cells/clones, in addition to AR+ cells.
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5.2.

Materials and methods

5.2.1. Animals and reagents
All AR+ and AR-KO LNCaP cell lines were regularly authenticated in our
institutional CCSG Cell Line Characterization Core and examined to be free of
mycoplasma

contamination.

Immunodeficient

mice,

NOD/SCID

(non-obese

diabetic/severe combined immunodeficiency) and NOD/SCID-IL2Rγ-/- (NSG), were
obtained from the Jackson Laboratory, and breeding colonies were maintained in
standard conditions in our animal core. All animal-related studies have been approved by
our Institutional Animal Care and Use Committee (IACUC) at the M.D. Anderson Cancer
Center (ACUF#00000923-RN00) and the Roswell Park Cancer Institute (animal
protocol#

1331M).

Therapeutic

reagents

used

in

this

study

included

Enzalutamide/MDV3100 (Selleck Chemicals, Cat# S1250).
5.2.2. Clonal and clongenic assays
For clonal assays, 5,000 AR-KO or AR+ cells were seeded in 6-well plates. After
two weeks, cells were stained with 1:20 giemsa and plates were scanned using an HP®
scanner. Cell clones were quantified using ImageJ software. For clonogenic assays, 500
AR-KO or AR+ cells were suspended in 100 µL of a 50% matrigel, 50% normal media
mixture, supplemented with 0.1 nM DHT or 2 µM enzalutamide, and spread carefully into
24-well plates. Fresh media with DHT and enzalutamide were changed every other day.
After two weeks, sphere numbers were enumerated under a phase-contrast microscope
and images were taken using an Olympus inverted epifluorescence microscope.
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5.2.3. AR-KO and AR+ competition assays
For in vitro assays, AR-KO cells were labeled with GFP via infection with pGIPZ
non-silencing GFP control plasmid at an MOI of 10. 5,000 AR-KO (GFP+) cells and 5,000
AR+ (RFP+) cells were mixed and seeded into a 6-well plate. Cell images were captured
using a JuLI™ Stage Real-Time microscope at 2 hr intervals. Three focal points in each
well were recorded and cell confluence data was measured using ImageJ software. For
in vivo tumor assays, 200,000 AR-KO (RFP-) cells and 200,000 AR+ (RFP+) cells were
mixed and injected into castrated or testosterone-implanted NSG mice. Two tumors were
harvested per time point and 10,000 single cells were analyzed per tumor using a BD
LSR II flow cytometer for the abundance of GFP+ and RFP+ cells.
5.2.4. BrdU incorporation assays
Cells at 50% confluence were incubated with 2 µM 5-Bromo-2'-deoxyuridine
(BrdU) for 5 hr. Cells were fixed with 4% PFA for 5 min and permeabilized with 1%
Triton-X100. DNA was denatured using 3 M hydrochloric acid in 1% Triton-X100 for 20
min and then treated with 0.1 M sodium borate for 15 min. Cells were blocked with
background sniper (BS996; Biocare Medical, Concord, CA) for 20 min and incubated
with mouse monoclonal anti-BrdU antibody (#B2531 Sigma, MO) for 5 hr at RT, followed
by incubation with goat anti-mouse IgG conjugated to Alexafluor 488. After
counterstaining

with

DAPI,

images

were

taken

using

an

Olympus

inverted

epifluorescence microscope.
5.2.5. Tumor regeneration assays
AR-KO and AR+ cells were suspended in 50% Matrigel and 50% normal media
and injected subcutaneously (s.c) into intact, castrated or testosterone-implanted
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NOD/SCID or NSG male mice (8-10 weeks old). Tumor size was measured twice per
week in two dimensions using a caliper. Tumor volume was calculated using the
following equation: 1/2 (length x width2). Animal body weight and health status were
monitored and recorded. At the end of the experiments, tumors were harvested, tumor
incidence, weight, and images were recorded.
5.2.6. Enzalutamide treatment
250,000 AR-KO cells were s.c-implanted into castrated NSG male mice (~6
weeks old), and 250,000 AR+ cells were s.c-implanted into intact NSG male mice (~6
weeks old). Once tumors were palpable, mice were randomly divided into two groups:
vehicle/control treated mice (n=10) and enzalutamide treated mice (n=10). Enzalutamide
was initially dissolved in DMSO at 90 mg/ml to make a stock solution, and then was
diluted in corn oil (Sigma; C8267) to achieve a 2.5 mg/ml working solution. Mice were
treated with 100 µL enzalutamide working solution intraperitoneally (i.p) 3 times per
week (30 mg/kg/week) in the treatment group. The mice in the control group were
treated with 100 µL corn oil (Sigma; C8267) with 2.5% DMSO 3 times per week.
5.2.7. IHC staining in FFPE (formalin fixed and paraffin-embedded) sections
Formalin fixed and paraffin-embedded (FFPE) sections

(4 µm) were

deparaffinized in xylene and hydrated in gradient alcohols to water. Slides were then
treated with 10 mM citrate buffer (pH 6.0) for antigen retrieval, blocked with 2.5% horse
serum, incubated with primary antibodies followed by corresponding secondary
antibodies, and then counterstained with hematoxylin. IHC images were captured via an
Olympus microscope.
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5.2.8. Statistic analysis
Unpaired two-tailed Student’s t-test was used to compare significance in clonal
assays, and to compare tumor weights and volumes obtained in in vivo experiments.
Chi-squared test was employed to compare tumor incidence. The results were presented
as mean ± S.D with a P value < 0.05 considered statistically significant.
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5.3.

Results

5.3.1. AR+ cells are more tumorigenic in androgen-proficient environment
To compare the clonal and sphere-formation abilities between AR+ and AR-KO
cells in an androgen-proficient environment, single cells were suspended in 2D and 3D
culture media supplemented with DHT (0.1 nM). After two weeks, AR-30 and AR-31 cells
gave rise to significantly more clones in the 2D culture, compared to the KO-03 or KO-16
cells (Figure 5-1, A). Additionally, AR+ clones formed larger and more spheres than ARKO clones (Figure 5-1, B). Results from the BrdU incorporation assay show a larger
percentage of AR+ cells in S-phase compared to AR-KO LNCaP cells, when cultured in
DHT supplemented conditions (Figure 5-2, A-B). In addition, AR+ clones showed
significant proliferation advantages compared to GFP-tagged AR-KO clones in a
competition assay with DHT supplement at 0.1 nM under a time-lapse microscope
(Figure 5-2, C-D).
In order to compare the in vivo tumorigenic abilities between the two isogenic cell
types, 500,000 each of AR-12, AR-31 and KO-03 and KO-16 cells were s.c-implanted
into intact male NOD-SCID mice. Results revealed that AR+ cells generated larger and a
greater overall number of tumors than AR-KO LNCaP cells (Figure 5-3, A). An
independent repeat experiment was conducted in intact male NSG mice s.c-implanted
with AR-12, AR-31, KO-01 and KO-03 cells. Consistent with previous results, AR+ cells
were much more tumorigenic compared to AR-KO cells (Figure 5-3, B). To eliminate
inter-animal variations and control androgen levels in each animal, we supplemented
NSG male mice with testosterone pellets and injected identical numbers of AR+ and ARKO LNCaP cells on opposite flanks in the same animal (i.e., AR+ cells on the right side
and AR-KO cells on the left) (Figure 5-4, A). During the in vivo assays, we consistently
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observed significantly larger tumors on the right flanks of mice (Figure 5-4, C). On day 63,
when endpoint tumors were harvested, we observed that the two AR+ clonal cells
generated a greater overall number of tumors (27/30) (number of mice with tumors/ total
number of mice injected) that were much larger (average weight: 0.65 g), when
compared to AR-KO cells, which generated fewer tumors (7/30) that were smaller (0.05
g) (Figure 5-4, B-D). IHC staining for AR expression in the endpoint tumors confirmed
positive AR expression in AR+ cell-derived xenografts, whereas AR-KO xenograft tumors
were negative for AR expression (Figure 5-3, E).
Together, this study provided direct evidence that in an androgen proficient
environment, AR+ LNCaP cells form more clones, spheres and tumors than AR-KO
LNCaP cells (Figure, 5-1 to 5-4). Thus, androgen-dependent proliferation in AR+ LNCaP
cells is critical for tumor formation.
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Figure 5-1 AR+ cells possess higher clonal and sphere-forming abilities in
androgen-proficient conditions than AR-KO cells
A. Quantification of clones formed by KO-03, KO-16, AR-30 and AR-31 cells in 2D
culture conditions using RPMI supplemented with 10% FBS + 0.1 nm DHT (upper
panel). Representative images of giemsa stained clones generated from the four
different clones are shown (lower panel). Scale bar: 1 cm.
B. Quantification of spheres formed by KO-03, KO-16, AR-30 and AR-31 cells in 3D
culture conditions using RPMI supplemented with 10% FBS + 0.1 nm DHT (upper
panel). Representative images of spheres generated from the four clones are shown
(lower panel). Scale bar: 1 mm.
Values represent mean ± SD of triplicates of the experiment. P values were calculated
using upaired Student’s t-test. Applies to both A and B.
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Figure 5-2 AR+ LNCaP cells are more proliferative than the isogenic AR-KO cells in
androgen-proficient conditions.
A-B. A greater percentage of DHT treated AR+ LNCaP cells were in the S-phase
compared to AR-KO LNCaP cells. A. Quantification of BrdU positive AR-KO and AR+
cells cultured in RPMI supplemented with 10% FBS + 0.1 nM DHT media (left panel).
Values represent mean ± SD of triplicates from three independent experiments. n
indicates the total number of cells analyzed. P values were calculated using upaired
Student’s t-test. B. Representative images of BrdU stained AR-KO and AR+ cells (right
panel). The percentage of BrdU positive cells is indicated on “Merge” images. Cell
numbers representing BrdU and DAPI positive cells are indicated. Scale bar: 250 µm.
C-D AR+ LNCaP cells exhibit proliferative advantages in androgen-proficient conditions
C. Quantification of DHT treated (0.1 nM) AR-KO (GFP) and AR+ (RFP) LNCaP cell
confluence measured daily and presented as fold change. 5,000 AR-KO (GFP+) cells
and 5,000 AR+ (RFP+) cells were mixed and seeded into a 6-well plate on day 0. Values
represent mean ± SD of triplicates of the experiment. D. Representative images of DHT
treated (0.1 nM) AR-KO and AR+ LNCaP cells on day 0 (upper panels) and day 7 (lower
panels). Percentages of fluorescent positive areas are indicated on the lower left corners
of the images. Scale bar: 250 µm.
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Figure 5-3 AR+ cells are more tumorigenic in intact NOD-SCID and NSG mice
compared to isogenic AR-KO LNCaP cells.
Results from two independent tumor regenerations assays: AR-12, AR-31, KO-01, KO03 and KO-16 cells (500,000) were subcutaneously (s.c) implanted in intact NOD-SCID
male mice (A) intact NSG mice (B). Images of endpoint tumors, as well as corresponding
tumor weight, tumor incidence, and P-values are shown. P-values for tumor weight and
tumor incidence were calculated using unpaired student’s t-test and Chi-squared test,
respectively.
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Figure 5-4 AR+ LNCaP cells are more tumorigenic in testosterone-supplemented
NSG mice than isogenic AR-KO cells.
A. Schematic depicting cell number and type, and mouse implantation sites in tumor
regeneration assays.
B. Images of endpoint tumors, with corresponding tumor weight, tumor incidence, and Pvalues. Small image shows four tumors of AR-30 and AR-31, harvested on day 56 due to
large sizes. P-values of tumor weight and tumor incidence were calculated using
unpaired Student’s t-test and Chi-squared test, respectively.
C. Representative images of two mice each s.c-implanted with AR+ LNCaP cells (right
flank) and AR-KO LNCaP cells (left flank). Note that both mice bear a tumor on their right
flanks (AR+ cells) but not on their left flanks (AR-KO cells).
D. Quantification of endpoint tumor weights in AR+ and AR-KO LNCaP cell experimental
groups.
E. Representative images of IHC staining for AR expression in endpoint tumors. Note
that tumors derived from AR+ LNCaP cells (AR-30 and AR-31) are positive for AR
expression whereas tumors derived from AR-KO LNCaP cells (KO-03 and KO-16) are
AR negative. Scale bar: 250 µm
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5.3.2. AR-KO LNCaP cells are resistant to castration and highly tumorigenic in
castrated mice
Our next aim was to determine how these observed tumorigenic abilities in
isogenic AR+ LNCaP and AR-KO LNCaP cells in androgen proficient mice differ when
assessed in castrated NSG mice. In our pilot experiments, AR-KO LNCaP clones
generated 10 tumors out of 16 injections (62.5%) whereas AR+ LNCaP clones generated
4 tumors out of 18 injections (22.2%) during a four-month span (Figure, 5-5). Additionally,
tumors derived from AR-KO LNCaP cells were four times larger than tumors derived
from AR+ LNCaP cells (Figure, 5-5). These results suggested that AR-KO LNCaP clonal
cells were resistant to castration and more tumorigenic than AR+ cells in androgen
ablated hosts. In order to confirm these observations, we performed a comprehensive
tumor regeneration assay in which identical numbers of isogenic AR-KO and AR+ LNCaP
cells (250,000 each) were implanted in the same castrated NSG mouse on opposite
flanks. Tumor size and incidence were closely monitored twice per week (Figure 5-6, A).
Among the three groups of cells tested, the group consisting of KO-16 and AR-31
(Figure 5-6, E), and the group consisting of KO-01 and AR-19 (Figure 5-6, F) showed
more AR-KO tumors (left flank) with significantly larger volumes (Figure 5-6, B) and
endpoint tumor weights (Figure 5-6, D) when compared to the corresponding AR+ tumors
(right flank). Additionally, the two groups KO-01 and AR-19 (Figure 5-6, F) and KO-03
and AR-30 (Figure 5-6, G) generated significantly more tumors in the left sides than in
the right sides. Overall, this data suggests that AR-KO LNCaP cells possess significantly
greater tumor regeneration ability in castrated hosts than AR+ LNCaP clones (Figure 5-6
C). IHC staining for AR expression status in tumor tissues confirmed the AR expression
in the endpoint tumors from AR-KO and AR+ clones (Figure 5-6, H). Taken together, our
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data illustrate that AR-KO LNCaP cells are intrinsically more tumorigenic in an androgendepleted environment than isogenic AR+ LNCaP cells.
Next, we explored the effects of systemic androgen levels on the relative
abundance of AR+ vs. AR- cells during tumor progression. To test this, the same number
of clonal AR+ and AR-KO LNCaP cells (250,000 each) were mixed at 50:50 and
implanted into testosterone-supplemented (n=15) and castrated NSG mice (n=15). As
the tumor progressed, we analyzed ratios of AR+ (RFP+) to AR-KO (RFP-) cells via flow
analysis (Figure 5-7, A). In androgen-supplemented mice (AD), tumors at week 4
harbored an average of 91.4% RFP+ cells and 8.6% RFP- cells (Figure 5-7, B red line).
The abundance of RFP+ cells increased at later time points such that the two tumors at
week 7 harbored 98.6% RFP+ and 1.14% RFP- cells, respectively (Figure 5-7, B red line).
The experimental AD group was terminated on week 7 due to large tumor sizes. In order
to mimic the transition from an AD to AI environment, mice from the AD group (n=7)
were castrated and had their testosterone pellets removed on week 4 (ADèAI group). In
this ADèAI group, the RFP+ AR+ LNCaP cells remained the dominant population (97.9%)
in the tumors when analyzed at week 7 (i.e. 3 weeks post castration) (Figure 5-7, B blue
line). However, by week 9, tumors in the ADèAI group showed significant increases in
AR-KO (RFP-) LNCaP cells to 69.4% and, in the meantime, AR+ LNCaP cells dropped to
30.6%. (Figure 5-7, B blue line).
In the castrated group (AI), two tumors analyzed at week 3 showed an average of
32.9% AR+ cells and 67.1% AR-KO cells (Figure 5-7, B black line), and these numbers
remained stable till week 9 (Figure 5-7, B black line) with AR-KO LNCaP cells being the
dominant subpopulation. Competition assays further demonstrated intrinsic differences
between AR+ and AR-KO clonal LNCaP cells in terms of tumor initiation and progression
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capabilities in different androgen contexts. In summary, AR+ PCa cells may be the
driving force of tumor development in AD environments, while AR-/lo PCa cells may play
an important role in the development of CRPC.
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Figure 5-5 AR-KO LNCaP cells are more tumorigenic than AR+ cells in castrated
hosts.
Endpoint tumors on day 118 of KO-03, KO-16, AR-12 and AR-31 regenerated in
castrated NSG mice. Images of endpoint tumors, tumor weight and tumor incidence with
correspenonding P-values. P-values of tumor weight were calculated using unpaired
Student’s t-test. P-values of tumor incidence were calculated using Chi-squared test.
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Figure 5-6 AR-KO LNCaP cells are more tumorigenic than AR+ LNCaP cells in the same castrated NSG mice
124

Figure 5-6 AR-KO LNCaP cells are more tumorigenic than AR+ LNCaP cells in the
same castrated NSG mice
A. Schematic of the experimental design: 250 K AR-KO LNCaP cells were injected
subcutaneously into the left flank of castrated NSG mice and 250 K AR+ LNCaP cells
were injected into the same mice on the right flank. Three groups of cells were used in
the experiment: KO-16 and AR-31 (n=12 mice), KO-01 and AR-19 (n=14 mice) and KO03 and AR-30 (n=11 mice).
B. Tumor volumes measured twice every week in animals with AR-KO (KO-16 and
KO01) and AR+ (AR-31 and AR-19) LNCaP cells injections starting from day 64 post
implantation (mean ± SD).
C. Tumor incidence observed twice every week in all three groups of animals starting
from day 64 post implantation (mean ± SD).
D. Graphical presentation of endpoint tumor weights in E and F.
E-G: Images of endpoint tumors, tumor weight and tumor incidence with corresponding
P-values. P-values of tumor weight were calculated using unpaired Student’s t-test. Pvalues of tumor incidence were calculated using Chi-squared test. Representative mice
images (right panels) bearing tumors only on the left flanks (AR-KO cells) but not on the
right flanks (AR+ cells).
H. Representative AR IHC staining images of the endpoint tumors. Scale bar: 250 µm
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Figure 5-7 The dynamics of AR-KO and AR+ LNCaP cells in animals with different
systemic androgen levels
A. Schematic of the experimental design depicting cell type, implantation in mice, and
subsequent experiments.
B. Normalized RFP+/RFP- ratios in the three groups at various time points. Two tumors
were analyzed at each condition and time point and data is shown as mean ± SD. The
red line represents ratios in tumors from T-supplemented mice (AD group). The blue
represents ratios in tumors from T-supplemented mice castrated on week 4 (ADèAI
group). The black line represents ratios in tumors from castrated mice analyzed starting
from week 3 (AI group).
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5.3.3. AR-KO LNCaP cells are resistant to Enzalutamide
In order to compare clonal and sphere-formation capacities between AR-KO and
AR+ LNCaP cells in response to AR antagonists, we seeded single cells in both 2D and
3D culture conditions supplemented with 2 µM Enzalutamide. AR-KO LNCaP cells
formed a significantly larger number of clones and spheres that were also larger in size
than AR+ LNCaP cells (Figure 5-8). Further, we assessed proliferation rates of the two
populations treated with enzalutamide via BrdU incorporation assays, single cell tracking
and in vitro competition assay (Figure 5-9). After pulsing enzalutamide treated (2 µM)
clonal cells with BrdU for 5 hr, an average of 22.45% AR-KO cells showed positive BrdU+
staining compared to 10.04% AR+ cells (p=0.0005) (Figure 5-9, A-B). Simultaneously, we
employed time lapse-based single-cell tracking to determine cell-cycle transit times in
AR+ and AR-KO LNCaP cells. In the 34 AR-KO and 32 AR+ cells analyzed, AR-KO cells
showed a shorter average cell-cycle transit time (20-hr) than isogenic AR+ cells (48-hr)
(Figure 5-9, C-D). Consistent with the single-cell analysis, competition assays, wherein
AR-KO (GFP+) clonal cells were mixed with AR+ (RFP+) clonal cells at a 1:1 ratio and
treated with 2 µM enzalutamide, revealed that AR-KO cells showed a significant growth
advantage compared to AR+ cells (Figure 5-9, E-F). AR-KO cells gained a 9.26-fold cell
number increase in 10 days compared to a 2.99-fold increases in AR+ cells (Figure 5-9,
E). Collectively, these data (Figure 5-8 and 5-9) provide evidence that AR-KO clonal
cells are resistant to enzalutamide treatment in vitro.
Lastly, we assessed resistance to enzalutamide in AR+ and AR-KO LNCaP cells
in vivo (Figure 5-10, A). In this experiment, 250,000 AR-KO clonal cells and 250,000 AR+
cells were implanted into castrated hosts (n=27) and into intact mice (n=15), respectively.
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When tumors emerged, mice were randomly divided into two groups. One group of mice
was treated with enzalutamide at 10 mg/kg three times a week (t.i.w.) dosage and the
other group was treated with 2.5% DMSO in corn oil. Tumors generated from AR+
LNCaP cells (4/8 tumors on day 0) were extremely sensitive to enzalutamide treatment
(Figure 5-10, B-C), as evidenced by the complete regression of tumors by the end of the
30-day enzalutamide treatment. However, AR-KO cells showed no significant differences
in terms of tumor initiation or tumor growth capability during enzalutamide treatment
(Figure 5-10, D-E).
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Figure 5-8 AR-KO LNCaP clonal cells form more clones and spheres than the
clonally derived AR+ LNCaP cells under Enzalutamide treatment.
A. Quantification of clones formed by KO-03, KO-16, AR-30 and AR-31 cells in 2D
culture conditions with RPMI supplemented with 10% FBS + 2 µM enzalutamide (upper
panel), and representative images (lower panel). Scale bar: 1 cm.
B. Quantification of spheres formed by KO-03, KO-16, AR-30 and AR-31 cells in 3D
culture conditions with RPMI supplemented with 10% FBS + 2 µM enzalutamide (upper
panel), and representative images (lower panel). Scale bar: 1 mm.
Values represent mean ± SD of triplicates of the experiment. P values were calculated
using upaired Student’s t-test. Applies to both A and B.

129

Figure 5-9 AR-KO LNCaP clonal cells are resistant to Enzalutamide treatment in
vitro

130

Figure 5-9 AR-KO LNCaP clonal cells are resistant to Enzalutamide treatment in
vitro
A-B: A greater percentage of enzalutamide treated AR-KO cells were in the S-phase
compared to AR+ cells. A. Quantification of BrdU positive AR-KO and AR+ cells. Values
represent mean ± SD of three independent experiments. n indicates total number of cells
analyzed. B. Representative images of BrdU staining in clonal AR-KO and AR+ cells.
Cell number and percentage of BrdU+ cells are displayed in lower left corners. Scale bar:
250 µm.
C-D: Enzalutamide treated (2 µM) AR-KO LNCaP cells display shorter cell-cycle transit
times than AR+ LNCaP cells as determined by time-lapse videomicroscopy. C.
Quantification of average cell-cycle transition times in AR-KO and AR+ LNCaP cells
based on the time-lapse tracking. D. Representative images of a single dividing AR-KO
cell (upper panels) and a quiescent AR+ cell (lower panels) at different time-points. Scale
bar: 250 µm.
E-F: Enzalutamide treated AR-KO LNCaP cells are more proliferative than AR+ LNCaP
cells. E. Quantification of enzalutamide treated (2 µM) AR-KO (GFP) and AR+ (RFP)
LNCaP cell numbers measured daily and presented as fold change. Values represent
mean ± SD of triplicates of the experiment. F. Representative images of enzalutamide
treated (2 µM) AR-KO and AR+ LNCaP cells on day 0 (upper panels) and day 10 (lower
panels). Scale bar: 250 µm.
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Figure 5-10 AR-KO LNCaP cells are resistant to Enzalutamide treatment in vivo
A. Schematic of the experiment. AR-KO and AR+ cells were injected into castrated mice
(n=27) and intact mice (n=15), respectively (day -30). Mice with AR-KO cell injections
were divided into two groups randomly when palpable tumors were detected (day 0).
Mice with AR+ cell injections were castrated and were divided into two groups randomly
when palpable tumors were detected (day 0). Enzalutamide (10 mg/kg t.i.w.) was given
in experimental groups and vehicle treatment (100 µL 2.5% DMSO in corn oil, t.i.w.) was
given in the control groups.
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B. Tumor volumes measured twice per week in animals implanted with AR+ (AR-30 and
AR-31) LNCaP cells (mean ± SD). The red line represents the enzalutamide treatment
group (n=8), and the black line represents the control group (n=7).
C. Images of endpoint tumors generated from AR+ (AR-30 and AR-31) LNCaP cells, and
corresponding tumor weight and tumor incidence with P-values indicated.
D. Tumor volumes measured twice per week in animals implanted with AR-KO (KO-03
and KO-16) LNCaP cells (mean ± SD). The red line represents the enzalutamide
treatment group (n=14), and the black line represents the control group (n=13).
E. Images of endpoint tumors generated from AR-KO (KO-03 and KO-16) LNCaP cells
and corresponding tumor weight and tumor incidence with P-values indicated. P-values
of tumor weight and tumor incidence were calculated using unpaired Student’s t-test and
Chi-squared test, respectively.
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5.4.

Discussion and perspectives
Primary PCa is largely a hormone-dependent disease as the majority of tumor

cells express AR and are highly androgen-dependent. Based on this observation, serum
levels of PSA, a transcriptional target of AR, are routinely screened for early disease
detection and disease progression, and androgen signaling remains the main therapeutic
target in PCa treatment [116]. The current clinical treatment plan for PCa starts with
prostatectomy and/or radiation. When post treatment serum PSA levels rise, patients are
treated with first-line hormonal therapy gonadotropin-releasing hormone (GnRH)
analogs. A subsequent rise in PSA level is indicative of primary CRPC (castration
resistant) disease and the patient is then put on second-line castration regimens to
suppress AR function (e.g., enzalutamide) and/or adrenal androgen (e.g., abiraterone).
Inevitably, secondary and tertiary CRPCs will occur with shorter intervals.
Strikingly, an increase in AR- tumor cells and/or tumors have been reported in
metastatic and treatment failed PCa patients [2, 117]. Due to the lack of tools enabling
the separation of AR+ and AR- tumor cells, the intrinsic differences between the two
subsets of PCa cells, in terms of tumor initiation and treatment response, remain to be
fully understood. In an effort to overcome this deficit, we utilized recent breakthrough
gene editing techniques to develop an optimized protocol for the generation of isogenic
AR+ and AR-KO LNCaP PCa cell populations. By using ZFN and CRISPR-cas9
technology, we successfully generated AR+ LNCaP clonal cells harboring one tagRFP
integrated AR allele and one wild type AR allele, and six AR-KO LNCaP clones. These
isogenic LNCaP models, for the first time, facilitated a thorough analysis of AR
heterogeneity including systematic comparisons of AR+ and AR- PCa cell tumorigenicity
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under different androgen levels, as well as treatment responses to AR antagonists in
vitro and in vivo.
In an androgen-supplemented environment, AR+ LNCaP cells exhibited a
significantly greater capacity in generating tumors than AR-KO LNCaP cells. In addition,
when both cell lines were combined and implanted in androgen-proficient mice, the AR+
LNCaP population quickly became dominant in AD tumors, resulting in almost
undetectable levels of AR-KO LNCaP cells. This observation was not surprising as
LNCaP cell proliferation is largely androgen dependent. On the other hand, this data also
suggested that testosterone may inhibit AR-/lo PCa cell proliferation through an unknown
pathway. A Phase II clinical trial of Bipolar Androgen Therapy (BAT), in which metastatic
CRPC patients one year post ADT were treated with superphysiologic doses of
testosterone and etoposide, showed promising results in controlling CRPC progression
[118]. However, the molecular mechanism behind the tumor-inhibitory effects of
androgen in PCa cells remains to be fully understood.
To mimic ADT in the clinic, we further interrogated the intrinsic differences in
tumor initiation capacities between the AR+ and AR- PCa cells in castrated hosts.
Approximately 40% of the AR+ LNCaP cells maintained the ablity to initiate tumors in a 4month span in castrated hosts (AI), compared to approximately 100% in AD hosts
(Figure 5-6). On one hand, this suggests that the AR+ LNCaP cells are sensitive to
castration. On the other hand, some AR+ tumors (i.e. AR-30) were equal in weight to ARKO tumors, indicating that the AR+ LNCaP tumor cells may have developed resistance to
castration via alternative pathways including AR overexpression. Data from previous
studies has shown that around 30% of human CRPC tumors harbored AR genomic
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amplification, and AR overexpression alone may be sufficient for CRPC development
[43, 119, 120]. Thus, results from these experiments provided the rationale for
developing novel androgen signaling antagonists for AR+ CRPC treatment.
Despite the obvious importance of AR signaling even in androgen deprived
environments, some data also suggest that AR- CRPC represents a more aggressive
subset of CRPC, which may be independent of androgen signaling and resistant to the
second generation of androgen antagonists [117, 121]. The need for definitive evidence
supporting the role of these aggressive AR- PCa cells under castration and/or anti-AR
treatment, is imperative. In our experiments, isogenic AR-KO LNCaP cells showed a
significant growth advantage compared to AR+ clonal LNCaP cells in castrated hosts by
generating significantly more tumors. In addition, in competition tumor assays, ARLNCaP cells remained the dominant cell population in tumors. Together, this data not
only demonstrate intrinsic higher tumorigenicity in AR- LNCaP cells in AI conditions than
AR+ LNCaP cells, it also indicates that AR- clones in CRPC may arise from pre-existing
AR-/lo cells in primary tumors.
Further, we illustrated differential responses to treatment with enzalutamide, an
AR antagonist, in AR+ and AR-KO LNCaP cells. As expected, AR+ LNCaP cells were
highly sensitive, while AR-KO LNCaP cells showed non-responsiveness in vitro and in
vivo. Various cell-signaling pathways accounting for AR- CRPC development have been
proposed. High glucocorticoid receptor (GR) was shown in enzalutamide resistant
human PCa and activation of GR in LNCaP cells conferred strong resistance to
enzalutamide [122]. MYCN gene amplification has also been noted in the AR- CRPC
[123]. N-myc overexpression in androgen-dependent LNCaP cells was shown to repress
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AR expression, and promote neuroendocrine differentiation in tumor cells [123].
Additionally, epigenetic regulators including EZH2 [124] and SOX2 [125] were shown to
facilitate the transition of AR+ PCa cells to AR- PCa cells and promote treatment
resistance. Collectively, our current research on CRPC, as well as studies from other
groups, urges drug development targeting both AR+ and AR- CRPC cells. However, there
is no drug available for targeting AR- cells in CRPC treatment.
The main significance of my research is, by using newly developed genetically
matched AR+ and AR-KO PCa cell clones, to demonstrate, for the first time, the intrinsic
biological and tumorigenic differences between the two PCa cell subpopulations. As ARKO cells are refractory to anti-androgen treatment, my work suggests that the AR-/lo PCa
cells pre-existing in untreated tumors will likely be selected for by ADT, that AR-/lo PCa
cells in CRPC will evade further castration treatment, and that the real impact in treating
CRPC will come from strategies to co-target both AR+ and AR-/lo PCa cells. In the future,
we aim to uncover novel therapeutics that specifically target AR- PCa cells. We propose
to utilize the isogenic PCa cells for large-scale small molecule and/or CRISPR-cas9
screening for potential drug targets. At the same time, we wish to answer the questions
raised from current data: 1) what are potential mechanisms of the androgen induced
repression of AR- PCa cells? 2) How is a subset of AR+ PCa cells able to initiate tumors
in castrated animals? 3) What pathways allow the AR-KO cells to be highly tumorigenic
in castrated hosts? To answer these questions, we propose to perform RNA-seq
analysis on in vitro culturing AR-KO and AR+ LNCaP cells and xenograft tumor tissues
generated from the cells in AD and AI conditions. Together, we wish to shed light on the
role of AR heterogeneity in CRPC and on developing novel PCa therapeutics.
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